Abstract

We describe a method to measure in vivo migration of human T cells by using the near-infrared (NIR) dye IRDye800CW. Labeling of Epstein–Barr virus-specific T cells with IRDye800CW did not affect viability, proliferation, or T cell function. Following tail vein injection into mice bearing subcutaneous tumors, the NIR signal could be measured in vivo at the tumor site. Analysis of tumors revealed T cell infiltration and an increased NIR signal, confirming T cell migration. To test specific migration with IRDye800CW, tumors were modified to express CCL5 to measure site-specific migration. The NIR signal was increased at CCL5-secreting tumors compared with control tumors. Together, these data suggest that IRDye800CW may be used to study the trafficking of T cells in a small animal model and may have potential as a short-term reporter molecule for human immunotherapy studies.

© 2008 Optical Society of America

Full Article  |  PDF Article

References

  • View by:
  • |
  • |
  • |

  1. C. M. Rooney, C. A. Smith, C. Y. Ng, S. Loftin, C. Li, R. A. Krance, M. K. Brenner, and H. E. Heslop, “Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation,” Lancet 345, 9-13 (1995).
    [CrossRef] [PubMed]
  2. H. E. Heslop, C. Y. Ng, C. Li, C. A. Smith, S. K. Loftin, R. A. Krance, M. K. Brenner, and C. M. Rooney, “Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes,” Nat. Med. 2, 551-555 (1996).
    [CrossRef] [PubMed]
  3. C. Yee, J. A. Thompson, P. Roche, D. R. Byrd, P. P. Lee, M. Piepkorn, K. Kenyon, M. M. Davis, S. R. Riddell, and P. D. Greenberg, “Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo,” J. Exp. Med. 192, 1637-1644 (2000).
    [CrossRef] [PubMed]
  4. B. A. Pockaj, R. M. Sherry, J. P. Wei, J. R. Yannelli, C. S. Carter, S. F. Leitman, J. A. Carasquillo, S. M. Steinberg, S. A. Rosenberg, and J. C. Yang, “Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response,” Cancer Res. 73, 1731-1737(1994).
  5. M. S. Mitchell, D. Darrah, D. Yeung, S. Halpern, A. Wallace, J. Voland, V. Jones, and J. Kan-Mitchell, “Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope,” J. Clin. Oncol. 20, 1075-1086(2002).
    [CrossRef] [PubMed]
  6. N. Meidenbauer, J. Marienhagen, M. Laumer, S. Vogl, J. Heymann, R. Andreesen, and A. Mackensen, “Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients,” J. Immunol. 170, 2161-2169 (2003).
    [PubMed]
  7. C. Botti, D. R. Negri, E. Seregni, V. Ramakrishna, F. Arienti, L. Maffioli, C. Lombardo, A. Bogni, C. Pascali, F. Crippa, S. Massaron, F. Remonti, S. Nerini-Molteni, S. Canevari, and E. Bombardieri, “Comparison of three different methods for radiolabelling human activated T lymphocytes,” Eur. J. Nucl. Med. Mol. Imaging 24, 497-504 (1997).
    [CrossRef]
  8. J. Hardy, M. Edinger, M. H. Bachmann, R. S. Negrin, C. G. Fathman, and C. H. Contag, “Bioluminescence imaging of lymphocyte trafficking in vivo,” Exp. Hematol. 29, 1353-1360 (2001).
    [CrossRef] [PubMed]
  9. A. Nakajima, C. M. Seroogy, M. R. Sandora, I. H. Tarner, G. L. Costa, C. Taylor-Edwards, M. H. Bachmann, C. H. Contag, and C. G. Fathman, “Antigen-specific T cell-mediated gene therapy in collagen-induced arthritis,” J. Clin. Invest. 107, 1293-1301 (2001).
    [CrossRef] [PubMed]
  10. G. L. Costa, M. R. Sandora, A. Nakajima, E. V. Nguyen, C. Taylor-Edwards, A. J. Slavin, C. H. Contag, C. G. Fathman, and J. M. Benson, “Adoptive immunotherapy of experimental autoimmune encephalomyelitis via T cell delivery of the IL-12 p40 subunit,” J. Immunol. 167, 2379-2387 (2001).
    [PubMed]
  11. C. E. Brown, R. P. Vishwanath, B. Aguilar, R. Starr, J. Najbauer, K. S. Aboody, and M. C. Jensen, “Tumor-derived chemokine MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively transferred T cells,” J. Immunol. 179, 3332-3341 (2007).
    [PubMed]
  12. J. Vera, B. Savoldo, S. Vigouroux, E. Biagi, M. Pule, C. Rossig, J. Wu, H. E. Heslop, C. M. Rooney, M. K. Brenner, and G. Dotti, “T lymphocytes redirected against the κ light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells,” Blood 108, 3890-3897 (2006).
    [CrossRef] [PubMed]
  13. B. Ballou, L. A. Ernst, and A. S. Waggoner, “Fluorescence imaging of tumors in vivo,” Curr. Med. Chem. 12, 795-805 (2005).
    [CrossRef] [PubMed]
  14. A. Moore, J. Grimm, B. Han, and P. Santamaria, “Tracking the recruitment of diabetogenic CD8+ T-cells to the pancreas in real time,” Diabetes 53, 1459-1466 (2004).
    [CrossRef] [PubMed]
  15. S. A. Anderson, J. Shukaliak-Quandt, E. K. Jordan, A. S. Arbab, R. Martin, H. McFarland, and J. A. Frank, “Magnetic resonance imaging of labeled T-cells in a mouse model of multiple sclerosis,” Ann. Neurol. 55, 654-659 (2004).
    [CrossRef] [PubMed]
  16. C. Billotey, C. Aspord, O. Beuf, E. Piaggio, F. Gazeau, M. F. Janier, and C. Thivolet, “T-cell homing to the pancreas in autoimmune mouse models of diabetes: in vivo MR imaging,” Radiology (Oak Brook, Ill.) 236, 579-587 (2005).
    [CrossRef]
  17. G. Koehne, M. Doubrovin, E. Doubrovina, P. Zanzonico, H. F. Gallardo, A. Ivanova, J. Balatoni, J. Teruya-Feldstein, G. Heller, C. May, V. Ponomarev, S. Ruan, R. Finn, R. G. Blasberg, W. Bornmann, I. Riviere, M. Sadelain, R. J. O'Reilly, S. M. Larson, and J. G. Tjuvajev, “Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes,” Nat. Biotechnol. 21, 405-413 (2003).
    [CrossRef] [PubMed]
  18. M. M. Doubrovin, E. S. Doubrovina, P. Zanzonico, M. Sadelain, S. M. Larson, and R. J. O'Reilly, “In vivo imaging and quantitation of adoptively transferred human antigen-specific T cells transduced to express a human norepinephrine transporter gene,” Cancer Res. 67, 11959-11969 (2007).
    [CrossRef] [PubMed]
  19. J. V. Frangioni, “In vivo near-infrared fluorescence imaging,” Curr. Opin. Chem. Biol. 7, 626-634 (2003).
    [CrossRef] [PubMed]
  20. F. K. Swirski, C. R. Berger, J. L. Figueiredo, T. R. Mempel, U. H. von Andrian, M. J. Pittet, and R. Weissleder, “A near-infrared cell tracker reagent for multiscopic in vivo imaging and quantification of leukocyte immune responses,” PLoS ONE 2(10), e1075 (24 October 2007).
    [CrossRef]
  21. W. Wang, S. Ke, Q. Wu, C. Charnsangavej, M. Gurfinkel, J. G. Gelovani, J. L. Abbruzzese, E. M. Sevick-Muraca, and C. Li, “Near-infrared optical imaging of integrin αvΒ3 in human tumor xenografts,” Mol. Imaging 3, 343-351 (2004).
    [CrossRef]
  22. J. P. Houston, S. Ke, W. Wang, C. Li, and E. M. Sevick-Muraca, “Quality analysis of in vivo near-infrared fluorescence and conventional gamma images acquired using a dual-labeled tumor-targeting probe,” J. Biomed. Opt. 10, 054010 (2005).
    [CrossRef] [PubMed]
  23. S. Ke, X. Wen, M. Gurfinkel, C. Charnsangavej, S. Wallace, E. M. Sevick-Muraca, and C. Li, “Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts,” Cancer Res. 63, 7870-7875 (2003).
    [PubMed]
  24. S. Gottschalk, O. L. Edwards, U. Sili, M. H. Huls, T. Goltsova, A. R. Davis, H. E. Heslop, and C. M. Rooney, “Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies,” Blood 101, 1905-1912 (2003).
    [CrossRef]
  25. S. Kwon, S. Ke, J. P. Houston, W. Wang, Q. Wu, C. Li, and E. M. Sevick-Muraca, “Imaging dose-dependent pharmacokinetics of an RGD-fluorescent dye conjugate targeted to αvΒ3 receptor expressed in Kaposi's sarcoma,” Mol. Imaging 4, 75-87 (2005).
    [PubMed]
  26. K. E. Adams, S. Ke, S. Kwon, F. Liang, Z. Fan, Y. Lu, K. Hirschi, M. E. Mawad, M. A. Barry, and E. M. Sevick-Muraca, “Comparison of visible and near-infrared wavelength-excitable fluorescent dyes for molecular imaging of cancer,” J. Biomed. Opt. 12, 024017 (2007).
    [CrossRef] [PubMed]
  27. A. M. Leen, U. Sili, B. Savoldo, A. M. Jewell, P. A. Piedra, M. K. Brenner, and C. M. Rooney, “Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications,” Blood 103, 1011-1019 (2003).
  28. C. Hess, T. K. Means, P. Autissier, T. Woodberry, M. Altfeld, M. M. Addo, N. Frahm, C. Brander, B. D. Walker, and A. D. Luster, “IL-8 responsiveness defines a subset of CD8 T cells poised to kill,” Blood 104, 3463-3471 (2004).
    [CrossRef] [PubMed]

2007

C. E. Brown, R. P. Vishwanath, B. Aguilar, R. Starr, J. Najbauer, K. S. Aboody, and M. C. Jensen, “Tumor-derived chemokine MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively transferred T cells,” J. Immunol. 179, 3332-3341 (2007).
[PubMed]

M. M. Doubrovin, E. S. Doubrovina, P. Zanzonico, M. Sadelain, S. M. Larson, and R. J. O'Reilly, “In vivo imaging and quantitation of adoptively transferred human antigen-specific T cells transduced to express a human norepinephrine transporter gene,” Cancer Res. 67, 11959-11969 (2007).
[CrossRef] [PubMed]

K. E. Adams, S. Ke, S. Kwon, F. Liang, Z. Fan, Y. Lu, K. Hirschi, M. E. Mawad, M. A. Barry, and E. M. Sevick-Muraca, “Comparison of visible and near-infrared wavelength-excitable fluorescent dyes for molecular imaging of cancer,” J. Biomed. Opt. 12, 024017 (2007).
[CrossRef] [PubMed]

2006

J. Vera, B. Savoldo, S. Vigouroux, E. Biagi, M. Pule, C. Rossig, J. Wu, H. E. Heslop, C. M. Rooney, M. K. Brenner, and G. Dotti, “T lymphocytes redirected against the κ light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells,” Blood 108, 3890-3897 (2006).
[CrossRef] [PubMed]

2005

B. Ballou, L. A. Ernst, and A. S. Waggoner, “Fluorescence imaging of tumors in vivo,” Curr. Med. Chem. 12, 795-805 (2005).
[CrossRef] [PubMed]

C. Billotey, C. Aspord, O. Beuf, E. Piaggio, F. Gazeau, M. F. Janier, and C. Thivolet, “T-cell homing to the pancreas in autoimmune mouse models of diabetes: in vivo MR imaging,” Radiology (Oak Brook, Ill.) 236, 579-587 (2005).
[CrossRef]

S. Kwon, S. Ke, J. P. Houston, W. Wang, Q. Wu, C. Li, and E. M. Sevick-Muraca, “Imaging dose-dependent pharmacokinetics of an RGD-fluorescent dye conjugate targeted to αvΒ3 receptor expressed in Kaposi's sarcoma,” Mol. Imaging 4, 75-87 (2005).
[PubMed]

J. P. Houston, S. Ke, W. Wang, C. Li, and E. M. Sevick-Muraca, “Quality analysis of in vivo near-infrared fluorescence and conventional gamma images acquired using a dual-labeled tumor-targeting probe,” J. Biomed. Opt. 10, 054010 (2005).
[CrossRef] [PubMed]

2004

W. Wang, S. Ke, Q. Wu, C. Charnsangavej, M. Gurfinkel, J. G. Gelovani, J. L. Abbruzzese, E. M. Sevick-Muraca, and C. Li, “Near-infrared optical imaging of integrin αvΒ3 in human tumor xenografts,” Mol. Imaging 3, 343-351 (2004).
[CrossRef]

C. Hess, T. K. Means, P. Autissier, T. Woodberry, M. Altfeld, M. M. Addo, N. Frahm, C. Brander, B. D. Walker, and A. D. Luster, “IL-8 responsiveness defines a subset of CD8 T cells poised to kill,” Blood 104, 3463-3471 (2004).
[CrossRef] [PubMed]

A. Moore, J. Grimm, B. Han, and P. Santamaria, “Tracking the recruitment of diabetogenic CD8+ T-cells to the pancreas in real time,” Diabetes 53, 1459-1466 (2004).
[CrossRef] [PubMed]

S. A. Anderson, J. Shukaliak-Quandt, E. K. Jordan, A. S. Arbab, R. Martin, H. McFarland, and J. A. Frank, “Magnetic resonance imaging of labeled T-cells in a mouse model of multiple sclerosis,” Ann. Neurol. 55, 654-659 (2004).
[CrossRef] [PubMed]

2003

G. Koehne, M. Doubrovin, E. Doubrovina, P. Zanzonico, H. F. Gallardo, A. Ivanova, J. Balatoni, J. Teruya-Feldstein, G. Heller, C. May, V. Ponomarev, S. Ruan, R. Finn, R. G. Blasberg, W. Bornmann, I. Riviere, M. Sadelain, R. J. O'Reilly, S. M. Larson, and J. G. Tjuvajev, “Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes,” Nat. Biotechnol. 21, 405-413 (2003).
[CrossRef] [PubMed]

J. V. Frangioni, “In vivo near-infrared fluorescence imaging,” Curr. Opin. Chem. Biol. 7, 626-634 (2003).
[CrossRef] [PubMed]

N. Meidenbauer, J. Marienhagen, M. Laumer, S. Vogl, J. Heymann, R. Andreesen, and A. Mackensen, “Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients,” J. Immunol. 170, 2161-2169 (2003).
[PubMed]

A. M. Leen, U. Sili, B. Savoldo, A. M. Jewell, P. A. Piedra, M. K. Brenner, and C. M. Rooney, “Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications,” Blood 103, 1011-1019 (2003).

S. Ke, X. Wen, M. Gurfinkel, C. Charnsangavej, S. Wallace, E. M. Sevick-Muraca, and C. Li, “Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts,” Cancer Res. 63, 7870-7875 (2003).
[PubMed]

S. Gottschalk, O. L. Edwards, U. Sili, M. H. Huls, T. Goltsova, A. R. Davis, H. E. Heslop, and C. M. Rooney, “Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies,” Blood 101, 1905-1912 (2003).
[CrossRef]

2002

M. S. Mitchell, D. Darrah, D. Yeung, S. Halpern, A. Wallace, J. Voland, V. Jones, and J. Kan-Mitchell, “Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope,” J. Clin. Oncol. 20, 1075-1086(2002).
[CrossRef] [PubMed]

2001

J. Hardy, M. Edinger, M. H. Bachmann, R. S. Negrin, C. G. Fathman, and C. H. Contag, “Bioluminescence imaging of lymphocyte trafficking in vivo,” Exp. Hematol. 29, 1353-1360 (2001).
[CrossRef] [PubMed]

A. Nakajima, C. M. Seroogy, M. R. Sandora, I. H. Tarner, G. L. Costa, C. Taylor-Edwards, M. H. Bachmann, C. H. Contag, and C. G. Fathman, “Antigen-specific T cell-mediated gene therapy in collagen-induced arthritis,” J. Clin. Invest. 107, 1293-1301 (2001).
[CrossRef] [PubMed]

G. L. Costa, M. R. Sandora, A. Nakajima, E. V. Nguyen, C. Taylor-Edwards, A. J. Slavin, C. H. Contag, C. G. Fathman, and J. M. Benson, “Adoptive immunotherapy of experimental autoimmune encephalomyelitis via T cell delivery of the IL-12 p40 subunit,” J. Immunol. 167, 2379-2387 (2001).
[PubMed]

2000

C. Yee, J. A. Thompson, P. Roche, D. R. Byrd, P. P. Lee, M. Piepkorn, K. Kenyon, M. M. Davis, S. R. Riddell, and P. D. Greenberg, “Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo,” J. Exp. Med. 192, 1637-1644 (2000).
[CrossRef] [PubMed]

1997

C. Botti, D. R. Negri, E. Seregni, V. Ramakrishna, F. Arienti, L. Maffioli, C. Lombardo, A. Bogni, C. Pascali, F. Crippa, S. Massaron, F. Remonti, S. Nerini-Molteni, S. Canevari, and E. Bombardieri, “Comparison of three different methods for radiolabelling human activated T lymphocytes,” Eur. J. Nucl. Med. Mol. Imaging 24, 497-504 (1997).
[CrossRef]

1996

H. E. Heslop, C. Y. Ng, C. Li, C. A. Smith, S. K. Loftin, R. A. Krance, M. K. Brenner, and C. M. Rooney, “Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes,” Nat. Med. 2, 551-555 (1996).
[CrossRef] [PubMed]

1995

C. M. Rooney, C. A. Smith, C. Y. Ng, S. Loftin, C. Li, R. A. Krance, M. K. Brenner, and H. E. Heslop, “Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation,” Lancet 345, 9-13 (1995).
[CrossRef] [PubMed]

1994

B. A. Pockaj, R. M. Sherry, J. P. Wei, J. R. Yannelli, C. S. Carter, S. F. Leitman, J. A. Carasquillo, S. M. Steinberg, S. A. Rosenberg, and J. C. Yang, “Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response,” Cancer Res. 73, 1731-1737(1994).

Abbruzzese, J. L.

W. Wang, S. Ke, Q. Wu, C. Charnsangavej, M. Gurfinkel, J. G. Gelovani, J. L. Abbruzzese, E. M. Sevick-Muraca, and C. Li, “Near-infrared optical imaging of integrin αvΒ3 in human tumor xenografts,” Mol. Imaging 3, 343-351 (2004).
[CrossRef]

Aboody, K. S.

C. E. Brown, R. P. Vishwanath, B. Aguilar, R. Starr, J. Najbauer, K. S. Aboody, and M. C. Jensen, “Tumor-derived chemokine MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively transferred T cells,” J. Immunol. 179, 3332-3341 (2007).
[PubMed]

Adams, K. E.

K. E. Adams, S. Ke, S. Kwon, F. Liang, Z. Fan, Y. Lu, K. Hirschi, M. E. Mawad, M. A. Barry, and E. M. Sevick-Muraca, “Comparison of visible and near-infrared wavelength-excitable fluorescent dyes for molecular imaging of cancer,” J. Biomed. Opt. 12, 024017 (2007).
[CrossRef] [PubMed]

Addo, M. M.

C. Hess, T. K. Means, P. Autissier, T. Woodberry, M. Altfeld, M. M. Addo, N. Frahm, C. Brander, B. D. Walker, and A. D. Luster, “IL-8 responsiveness defines a subset of CD8 T cells poised to kill,” Blood 104, 3463-3471 (2004).
[CrossRef] [PubMed]

Aguilar, B.

C. E. Brown, R. P. Vishwanath, B. Aguilar, R. Starr, J. Najbauer, K. S. Aboody, and M. C. Jensen, “Tumor-derived chemokine MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively transferred T cells,” J. Immunol. 179, 3332-3341 (2007).
[PubMed]

Altfeld, M.

C. Hess, T. K. Means, P. Autissier, T. Woodberry, M. Altfeld, M. M. Addo, N. Frahm, C. Brander, B. D. Walker, and A. D. Luster, “IL-8 responsiveness defines a subset of CD8 T cells poised to kill,” Blood 104, 3463-3471 (2004).
[CrossRef] [PubMed]

Anderson, S. A.

S. A. Anderson, J. Shukaliak-Quandt, E. K. Jordan, A. S. Arbab, R. Martin, H. McFarland, and J. A. Frank, “Magnetic resonance imaging of labeled T-cells in a mouse model of multiple sclerosis,” Ann. Neurol. 55, 654-659 (2004).
[CrossRef] [PubMed]

Andreesen, R.

N. Meidenbauer, J. Marienhagen, M. Laumer, S. Vogl, J. Heymann, R. Andreesen, and A. Mackensen, “Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients,” J. Immunol. 170, 2161-2169 (2003).
[PubMed]

Arbab, A. S.

S. A. Anderson, J. Shukaliak-Quandt, E. K. Jordan, A. S. Arbab, R. Martin, H. McFarland, and J. A. Frank, “Magnetic resonance imaging of labeled T-cells in a mouse model of multiple sclerosis,” Ann. Neurol. 55, 654-659 (2004).
[CrossRef] [PubMed]

Arienti, F.

C. Botti, D. R. Negri, E. Seregni, V. Ramakrishna, F. Arienti, L. Maffioli, C. Lombardo, A. Bogni, C. Pascali, F. Crippa, S. Massaron, F. Remonti, S. Nerini-Molteni, S. Canevari, and E. Bombardieri, “Comparison of three different methods for radiolabelling human activated T lymphocytes,” Eur. J. Nucl. Med. Mol. Imaging 24, 497-504 (1997).
[CrossRef]

Aspord, C.

C. Billotey, C. Aspord, O. Beuf, E. Piaggio, F. Gazeau, M. F. Janier, and C. Thivolet, “T-cell homing to the pancreas in autoimmune mouse models of diabetes: in vivo MR imaging,” Radiology (Oak Brook, Ill.) 236, 579-587 (2005).
[CrossRef]

Autissier, P.

C. Hess, T. K. Means, P. Autissier, T. Woodberry, M. Altfeld, M. M. Addo, N. Frahm, C. Brander, B. D. Walker, and A. D. Luster, “IL-8 responsiveness defines a subset of CD8 T cells poised to kill,” Blood 104, 3463-3471 (2004).
[CrossRef] [PubMed]

Bachmann, M. H.

J. Hardy, M. Edinger, M. H. Bachmann, R. S. Negrin, C. G. Fathman, and C. H. Contag, “Bioluminescence imaging of lymphocyte trafficking in vivo,” Exp. Hematol. 29, 1353-1360 (2001).
[CrossRef] [PubMed]

A. Nakajima, C. M. Seroogy, M. R. Sandora, I. H. Tarner, G. L. Costa, C. Taylor-Edwards, M. H. Bachmann, C. H. Contag, and C. G. Fathman, “Antigen-specific T cell-mediated gene therapy in collagen-induced arthritis,” J. Clin. Invest. 107, 1293-1301 (2001).
[CrossRef] [PubMed]

Balatoni, J.

G. Koehne, M. Doubrovin, E. Doubrovina, P. Zanzonico, H. F. Gallardo, A. Ivanova, J. Balatoni, J. Teruya-Feldstein, G. Heller, C. May, V. Ponomarev, S. Ruan, R. Finn, R. G. Blasberg, W. Bornmann, I. Riviere, M. Sadelain, R. J. O'Reilly, S. M. Larson, and J. G. Tjuvajev, “Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes,” Nat. Biotechnol. 21, 405-413 (2003).
[CrossRef] [PubMed]

Ballou, B.

B. Ballou, L. A. Ernst, and A. S. Waggoner, “Fluorescence imaging of tumors in vivo,” Curr. Med. Chem. 12, 795-805 (2005).
[CrossRef] [PubMed]

Barry, M. A.

K. E. Adams, S. Ke, S. Kwon, F. Liang, Z. Fan, Y. Lu, K. Hirschi, M. E. Mawad, M. A. Barry, and E. M. Sevick-Muraca, “Comparison of visible and near-infrared wavelength-excitable fluorescent dyes for molecular imaging of cancer,” J. Biomed. Opt. 12, 024017 (2007).
[CrossRef] [PubMed]

Benson, J. M.

G. L. Costa, M. R. Sandora, A. Nakajima, E. V. Nguyen, C. Taylor-Edwards, A. J. Slavin, C. H. Contag, C. G. Fathman, and J. M. Benson, “Adoptive immunotherapy of experimental autoimmune encephalomyelitis via T cell delivery of the IL-12 p40 subunit,” J. Immunol. 167, 2379-2387 (2001).
[PubMed]

Berger, C. R.

F. K. Swirski, C. R. Berger, J. L. Figueiredo, T. R. Mempel, U. H. von Andrian, M. J. Pittet, and R. Weissleder, “A near-infrared cell tracker reagent for multiscopic in vivo imaging and quantification of leukocyte immune responses,” PLoS ONE 2(10), e1075 (24 October 2007).
[CrossRef]

Beuf, O.

C. Billotey, C. Aspord, O. Beuf, E. Piaggio, F. Gazeau, M. F. Janier, and C. Thivolet, “T-cell homing to the pancreas in autoimmune mouse models of diabetes: in vivo MR imaging,” Radiology (Oak Brook, Ill.) 236, 579-587 (2005).
[CrossRef]

Biagi, E.

J. Vera, B. Savoldo, S. Vigouroux, E. Biagi, M. Pule, C. Rossig, J. Wu, H. E. Heslop, C. M. Rooney, M. K. Brenner, and G. Dotti, “T lymphocytes redirected against the κ light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells,” Blood 108, 3890-3897 (2006).
[CrossRef] [PubMed]

Billotey, C.

C. Billotey, C. Aspord, O. Beuf, E. Piaggio, F. Gazeau, M. F. Janier, and C. Thivolet, “T-cell homing to the pancreas in autoimmune mouse models of diabetes: in vivo MR imaging,” Radiology (Oak Brook, Ill.) 236, 579-587 (2005).
[CrossRef]

Blasberg, R. G.

G. Koehne, M. Doubrovin, E. Doubrovina, P. Zanzonico, H. F. Gallardo, A. Ivanova, J. Balatoni, J. Teruya-Feldstein, G. Heller, C. May, V. Ponomarev, S. Ruan, R. Finn, R. G. Blasberg, W. Bornmann, I. Riviere, M. Sadelain, R. J. O'Reilly, S. M. Larson, and J. G. Tjuvajev, “Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes,” Nat. Biotechnol. 21, 405-413 (2003).
[CrossRef] [PubMed]

Bogni, A.

C. Botti, D. R. Negri, E. Seregni, V. Ramakrishna, F. Arienti, L. Maffioli, C. Lombardo, A. Bogni, C. Pascali, F. Crippa, S. Massaron, F. Remonti, S. Nerini-Molteni, S. Canevari, and E. Bombardieri, “Comparison of three different methods for radiolabelling human activated T lymphocytes,” Eur. J. Nucl. Med. Mol. Imaging 24, 497-504 (1997).
[CrossRef]

Bombardieri, E.

C. Botti, D. R. Negri, E. Seregni, V. Ramakrishna, F. Arienti, L. Maffioli, C. Lombardo, A. Bogni, C. Pascali, F. Crippa, S. Massaron, F. Remonti, S. Nerini-Molteni, S. Canevari, and E. Bombardieri, “Comparison of three different methods for radiolabelling human activated T lymphocytes,” Eur. J. Nucl. Med. Mol. Imaging 24, 497-504 (1997).
[CrossRef]

Bornmann, W.

G. Koehne, M. Doubrovin, E. Doubrovina, P. Zanzonico, H. F. Gallardo, A. Ivanova, J. Balatoni, J. Teruya-Feldstein, G. Heller, C. May, V. Ponomarev, S. Ruan, R. Finn, R. G. Blasberg, W. Bornmann, I. Riviere, M. Sadelain, R. J. O'Reilly, S. M. Larson, and J. G. Tjuvajev, “Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes,” Nat. Biotechnol. 21, 405-413 (2003).
[CrossRef] [PubMed]

Botti, C.

C. Botti, D. R. Negri, E. Seregni, V. Ramakrishna, F. Arienti, L. Maffioli, C. Lombardo, A. Bogni, C. Pascali, F. Crippa, S. Massaron, F. Remonti, S. Nerini-Molteni, S. Canevari, and E. Bombardieri, “Comparison of three different methods for radiolabelling human activated T lymphocytes,” Eur. J. Nucl. Med. Mol. Imaging 24, 497-504 (1997).
[CrossRef]

Brander, C.

C. Hess, T. K. Means, P. Autissier, T. Woodberry, M. Altfeld, M. M. Addo, N. Frahm, C. Brander, B. D. Walker, and A. D. Luster, “IL-8 responsiveness defines a subset of CD8 T cells poised to kill,” Blood 104, 3463-3471 (2004).
[CrossRef] [PubMed]

Brenner, M. K.

J. Vera, B. Savoldo, S. Vigouroux, E. Biagi, M. Pule, C. Rossig, J. Wu, H. E. Heslop, C. M. Rooney, M. K. Brenner, and G. Dotti, “T lymphocytes redirected against the κ light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells,” Blood 108, 3890-3897 (2006).
[CrossRef] [PubMed]

A. M. Leen, U. Sili, B. Savoldo, A. M. Jewell, P. A. Piedra, M. K. Brenner, and C. M. Rooney, “Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications,” Blood 103, 1011-1019 (2003).

H. E. Heslop, C. Y. Ng, C. Li, C. A. Smith, S. K. Loftin, R. A. Krance, M. K. Brenner, and C. M. Rooney, “Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes,” Nat. Med. 2, 551-555 (1996).
[CrossRef] [PubMed]

C. M. Rooney, C. A. Smith, C. Y. Ng, S. Loftin, C. Li, R. A. Krance, M. K. Brenner, and H. E. Heslop, “Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation,” Lancet 345, 9-13 (1995).
[CrossRef] [PubMed]

Brown, C. E.

C. E. Brown, R. P. Vishwanath, B. Aguilar, R. Starr, J. Najbauer, K. S. Aboody, and M. C. Jensen, “Tumor-derived chemokine MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively transferred T cells,” J. Immunol. 179, 3332-3341 (2007).
[PubMed]

Byrd, D. R.

C. Yee, J. A. Thompson, P. Roche, D. R. Byrd, P. P. Lee, M. Piepkorn, K. Kenyon, M. M. Davis, S. R. Riddell, and P. D. Greenberg, “Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo,” J. Exp. Med. 192, 1637-1644 (2000).
[CrossRef] [PubMed]

Canevari, S.

C. Botti, D. R. Negri, E. Seregni, V. Ramakrishna, F. Arienti, L. Maffioli, C. Lombardo, A. Bogni, C. Pascali, F. Crippa, S. Massaron, F. Remonti, S. Nerini-Molteni, S. Canevari, and E. Bombardieri, “Comparison of three different methods for radiolabelling human activated T lymphocytes,” Eur. J. Nucl. Med. Mol. Imaging 24, 497-504 (1997).
[CrossRef]

Carasquillo, J. A.

B. A. Pockaj, R. M. Sherry, J. P. Wei, J. R. Yannelli, C. S. Carter, S. F. Leitman, J. A. Carasquillo, S. M. Steinberg, S. A. Rosenberg, and J. C. Yang, “Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response,” Cancer Res. 73, 1731-1737(1994).

Carter, C. S.

B. A. Pockaj, R. M. Sherry, J. P. Wei, J. R. Yannelli, C. S. Carter, S. F. Leitman, J. A. Carasquillo, S. M. Steinberg, S. A. Rosenberg, and J. C. Yang, “Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response,” Cancer Res. 73, 1731-1737(1994).

Charnsangavej, C.

W. Wang, S. Ke, Q. Wu, C. Charnsangavej, M. Gurfinkel, J. G. Gelovani, J. L. Abbruzzese, E. M. Sevick-Muraca, and C. Li, “Near-infrared optical imaging of integrin αvΒ3 in human tumor xenografts,” Mol. Imaging 3, 343-351 (2004).
[CrossRef]

S. Ke, X. Wen, M. Gurfinkel, C. Charnsangavej, S. Wallace, E. M. Sevick-Muraca, and C. Li, “Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts,” Cancer Res. 63, 7870-7875 (2003).
[PubMed]

Contag, C. H.

A. Nakajima, C. M. Seroogy, M. R. Sandora, I. H. Tarner, G. L. Costa, C. Taylor-Edwards, M. H. Bachmann, C. H. Contag, and C. G. Fathman, “Antigen-specific T cell-mediated gene therapy in collagen-induced arthritis,” J. Clin. Invest. 107, 1293-1301 (2001).
[CrossRef] [PubMed]

J. Hardy, M. Edinger, M. H. Bachmann, R. S. Negrin, C. G. Fathman, and C. H. Contag, “Bioluminescence imaging of lymphocyte trafficking in vivo,” Exp. Hematol. 29, 1353-1360 (2001).
[CrossRef] [PubMed]

G. L. Costa, M. R. Sandora, A. Nakajima, E. V. Nguyen, C. Taylor-Edwards, A. J. Slavin, C. H. Contag, C. G. Fathman, and J. M. Benson, “Adoptive immunotherapy of experimental autoimmune encephalomyelitis via T cell delivery of the IL-12 p40 subunit,” J. Immunol. 167, 2379-2387 (2001).
[PubMed]

Costa, G. L.

G. L. Costa, M. R. Sandora, A. Nakajima, E. V. Nguyen, C. Taylor-Edwards, A. J. Slavin, C. H. Contag, C. G. Fathman, and J. M. Benson, “Adoptive immunotherapy of experimental autoimmune encephalomyelitis via T cell delivery of the IL-12 p40 subunit,” J. Immunol. 167, 2379-2387 (2001).
[PubMed]

A. Nakajima, C. M. Seroogy, M. R. Sandora, I. H. Tarner, G. L. Costa, C. Taylor-Edwards, M. H. Bachmann, C. H. Contag, and C. G. Fathman, “Antigen-specific T cell-mediated gene therapy in collagen-induced arthritis,” J. Clin. Invest. 107, 1293-1301 (2001).
[CrossRef] [PubMed]

Crippa, F.

C. Botti, D. R. Negri, E. Seregni, V. Ramakrishna, F. Arienti, L. Maffioli, C. Lombardo, A. Bogni, C. Pascali, F. Crippa, S. Massaron, F. Remonti, S. Nerini-Molteni, S. Canevari, and E. Bombardieri, “Comparison of three different methods for radiolabelling human activated T lymphocytes,” Eur. J. Nucl. Med. Mol. Imaging 24, 497-504 (1997).
[CrossRef]

Darrah, D.

M. S. Mitchell, D. Darrah, D. Yeung, S. Halpern, A. Wallace, J. Voland, V. Jones, and J. Kan-Mitchell, “Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope,” J. Clin. Oncol. 20, 1075-1086(2002).
[CrossRef] [PubMed]

Davis, A. R.

S. Gottschalk, O. L. Edwards, U. Sili, M. H. Huls, T. Goltsova, A. R. Davis, H. E. Heslop, and C. M. Rooney, “Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies,” Blood 101, 1905-1912 (2003).
[CrossRef]

Davis, M. M.

C. Yee, J. A. Thompson, P. Roche, D. R. Byrd, P. P. Lee, M. Piepkorn, K. Kenyon, M. M. Davis, S. R. Riddell, and P. D. Greenberg, “Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo,” J. Exp. Med. 192, 1637-1644 (2000).
[CrossRef] [PubMed]

Dotti, G.

J. Vera, B. Savoldo, S. Vigouroux, E. Biagi, M. Pule, C. Rossig, J. Wu, H. E. Heslop, C. M. Rooney, M. K. Brenner, and G. Dotti, “T lymphocytes redirected against the κ light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells,” Blood 108, 3890-3897 (2006).
[CrossRef] [PubMed]

Doubrovin, M.

G. Koehne, M. Doubrovin, E. Doubrovina, P. Zanzonico, H. F. Gallardo, A. Ivanova, J. Balatoni, J. Teruya-Feldstein, G. Heller, C. May, V. Ponomarev, S. Ruan, R. Finn, R. G. Blasberg, W. Bornmann, I. Riviere, M. Sadelain, R. J. O'Reilly, S. M. Larson, and J. G. Tjuvajev, “Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes,” Nat. Biotechnol. 21, 405-413 (2003).
[CrossRef] [PubMed]

Doubrovin, M. M.

M. M. Doubrovin, E. S. Doubrovina, P. Zanzonico, M. Sadelain, S. M. Larson, and R. J. O'Reilly, “In vivo imaging and quantitation of adoptively transferred human antigen-specific T cells transduced to express a human norepinephrine transporter gene,” Cancer Res. 67, 11959-11969 (2007).
[CrossRef] [PubMed]

Doubrovina, E.

G. Koehne, M. Doubrovin, E. Doubrovina, P. Zanzonico, H. F. Gallardo, A. Ivanova, J. Balatoni, J. Teruya-Feldstein, G. Heller, C. May, V. Ponomarev, S. Ruan, R. Finn, R. G. Blasberg, W. Bornmann, I. Riviere, M. Sadelain, R. J. O'Reilly, S. M. Larson, and J. G. Tjuvajev, “Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes,” Nat. Biotechnol. 21, 405-413 (2003).
[CrossRef] [PubMed]

Doubrovina, E. S.

M. M. Doubrovin, E. S. Doubrovina, P. Zanzonico, M. Sadelain, S. M. Larson, and R. J. O'Reilly, “In vivo imaging and quantitation of adoptively transferred human antigen-specific T cells transduced to express a human norepinephrine transporter gene,” Cancer Res. 67, 11959-11969 (2007).
[CrossRef] [PubMed]

Edinger, M.

J. Hardy, M. Edinger, M. H. Bachmann, R. S. Negrin, C. G. Fathman, and C. H. Contag, “Bioluminescence imaging of lymphocyte trafficking in vivo,” Exp. Hematol. 29, 1353-1360 (2001).
[CrossRef] [PubMed]

Edwards, O. L.

S. Gottschalk, O. L. Edwards, U. Sili, M. H. Huls, T. Goltsova, A. R. Davis, H. E. Heslop, and C. M. Rooney, “Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies,” Blood 101, 1905-1912 (2003).
[CrossRef]

Ernst, L. A.

B. Ballou, L. A. Ernst, and A. S. Waggoner, “Fluorescence imaging of tumors in vivo,” Curr. Med. Chem. 12, 795-805 (2005).
[CrossRef] [PubMed]

Fan, Z.

K. E. Adams, S. Ke, S. Kwon, F. Liang, Z. Fan, Y. Lu, K. Hirschi, M. E. Mawad, M. A. Barry, and E. M. Sevick-Muraca, “Comparison of visible and near-infrared wavelength-excitable fluorescent dyes for molecular imaging of cancer,” J. Biomed. Opt. 12, 024017 (2007).
[CrossRef] [PubMed]

Fathman, C. G.

J. Hardy, M. Edinger, M. H. Bachmann, R. S. Negrin, C. G. Fathman, and C. H. Contag, “Bioluminescence imaging of lymphocyte trafficking in vivo,” Exp. Hematol. 29, 1353-1360 (2001).
[CrossRef] [PubMed]

A. Nakajima, C. M. Seroogy, M. R. Sandora, I. H. Tarner, G. L. Costa, C. Taylor-Edwards, M. H. Bachmann, C. H. Contag, and C. G. Fathman, “Antigen-specific T cell-mediated gene therapy in collagen-induced arthritis,” J. Clin. Invest. 107, 1293-1301 (2001).
[CrossRef] [PubMed]

G. L. Costa, M. R. Sandora, A. Nakajima, E. V. Nguyen, C. Taylor-Edwards, A. J. Slavin, C. H. Contag, C. G. Fathman, and J. M. Benson, “Adoptive immunotherapy of experimental autoimmune encephalomyelitis via T cell delivery of the IL-12 p40 subunit,” J. Immunol. 167, 2379-2387 (2001).
[PubMed]

Figueiredo, J. L.

F. K. Swirski, C. R. Berger, J. L. Figueiredo, T. R. Mempel, U. H. von Andrian, M. J. Pittet, and R. Weissleder, “A near-infrared cell tracker reagent for multiscopic in vivo imaging and quantification of leukocyte immune responses,” PLoS ONE 2(10), e1075 (24 October 2007).
[CrossRef]

Finn, R.

G. Koehne, M. Doubrovin, E. Doubrovina, P. Zanzonico, H. F. Gallardo, A. Ivanova, J. Balatoni, J. Teruya-Feldstein, G. Heller, C. May, V. Ponomarev, S. Ruan, R. Finn, R. G. Blasberg, W. Bornmann, I. Riviere, M. Sadelain, R. J. O'Reilly, S. M. Larson, and J. G. Tjuvajev, “Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes,” Nat. Biotechnol. 21, 405-413 (2003).
[CrossRef] [PubMed]

Frahm, N.

C. Hess, T. K. Means, P. Autissier, T. Woodberry, M. Altfeld, M. M. Addo, N. Frahm, C. Brander, B. D. Walker, and A. D. Luster, “IL-8 responsiveness defines a subset of CD8 T cells poised to kill,” Blood 104, 3463-3471 (2004).
[CrossRef] [PubMed]

Frangioni, J. V.

J. V. Frangioni, “In vivo near-infrared fluorescence imaging,” Curr. Opin. Chem. Biol. 7, 626-634 (2003).
[CrossRef] [PubMed]

Frank, J. A.

S. A. Anderson, J. Shukaliak-Quandt, E. K. Jordan, A. S. Arbab, R. Martin, H. McFarland, and J. A. Frank, “Magnetic resonance imaging of labeled T-cells in a mouse model of multiple sclerosis,” Ann. Neurol. 55, 654-659 (2004).
[CrossRef] [PubMed]

Gallardo, H. F.

G. Koehne, M. Doubrovin, E. Doubrovina, P. Zanzonico, H. F. Gallardo, A. Ivanova, J. Balatoni, J. Teruya-Feldstein, G. Heller, C. May, V. Ponomarev, S. Ruan, R. Finn, R. G. Blasberg, W. Bornmann, I. Riviere, M. Sadelain, R. J. O'Reilly, S. M. Larson, and J. G. Tjuvajev, “Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes,” Nat. Biotechnol. 21, 405-413 (2003).
[CrossRef] [PubMed]

Gazeau, F.

C. Billotey, C. Aspord, O. Beuf, E. Piaggio, F. Gazeau, M. F. Janier, and C. Thivolet, “T-cell homing to the pancreas in autoimmune mouse models of diabetes: in vivo MR imaging,” Radiology (Oak Brook, Ill.) 236, 579-587 (2005).
[CrossRef]

Gelovani, J. G.

W. Wang, S. Ke, Q. Wu, C. Charnsangavej, M. Gurfinkel, J. G. Gelovani, J. L. Abbruzzese, E. M. Sevick-Muraca, and C. Li, “Near-infrared optical imaging of integrin αvΒ3 in human tumor xenografts,” Mol. Imaging 3, 343-351 (2004).
[CrossRef]

Goltsova, T.

S. Gottschalk, O. L. Edwards, U. Sili, M. H. Huls, T. Goltsova, A. R. Davis, H. E. Heslop, and C. M. Rooney, “Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies,” Blood 101, 1905-1912 (2003).
[CrossRef]

Gottschalk, S.

S. Gottschalk, O. L. Edwards, U. Sili, M. H. Huls, T. Goltsova, A. R. Davis, H. E. Heslop, and C. M. Rooney, “Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies,” Blood 101, 1905-1912 (2003).
[CrossRef]

Greenberg, P. D.

C. Yee, J. A. Thompson, P. Roche, D. R. Byrd, P. P. Lee, M. Piepkorn, K. Kenyon, M. M. Davis, S. R. Riddell, and P. D. Greenberg, “Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo,” J. Exp. Med. 192, 1637-1644 (2000).
[CrossRef] [PubMed]

Grimm, J.

A. Moore, J. Grimm, B. Han, and P. Santamaria, “Tracking the recruitment of diabetogenic CD8+ T-cells to the pancreas in real time,” Diabetes 53, 1459-1466 (2004).
[CrossRef] [PubMed]

Gurfinkel, M.

W. Wang, S. Ke, Q. Wu, C. Charnsangavej, M. Gurfinkel, J. G. Gelovani, J. L. Abbruzzese, E. M. Sevick-Muraca, and C. Li, “Near-infrared optical imaging of integrin αvΒ3 in human tumor xenografts,” Mol. Imaging 3, 343-351 (2004).
[CrossRef]

S. Ke, X. Wen, M. Gurfinkel, C. Charnsangavej, S. Wallace, E. M. Sevick-Muraca, and C. Li, “Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts,” Cancer Res. 63, 7870-7875 (2003).
[PubMed]

Halpern, S.

M. S. Mitchell, D. Darrah, D. Yeung, S. Halpern, A. Wallace, J. Voland, V. Jones, and J. Kan-Mitchell, “Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope,” J. Clin. Oncol. 20, 1075-1086(2002).
[CrossRef] [PubMed]

Han, B.

A. Moore, J. Grimm, B. Han, and P. Santamaria, “Tracking the recruitment of diabetogenic CD8+ T-cells to the pancreas in real time,” Diabetes 53, 1459-1466 (2004).
[CrossRef] [PubMed]

Hardy, J.

J. Hardy, M. Edinger, M. H. Bachmann, R. S. Negrin, C. G. Fathman, and C. H. Contag, “Bioluminescence imaging of lymphocyte trafficking in vivo,” Exp. Hematol. 29, 1353-1360 (2001).
[CrossRef] [PubMed]

Heller, G.

G. Koehne, M. Doubrovin, E. Doubrovina, P. Zanzonico, H. F. Gallardo, A. Ivanova, J. Balatoni, J. Teruya-Feldstein, G. Heller, C. May, V. Ponomarev, S. Ruan, R. Finn, R. G. Blasberg, W. Bornmann, I. Riviere, M. Sadelain, R. J. O'Reilly, S. M. Larson, and J. G. Tjuvajev, “Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes,” Nat. Biotechnol. 21, 405-413 (2003).
[CrossRef] [PubMed]

Heslop, H. E.

J. Vera, B. Savoldo, S. Vigouroux, E. Biagi, M. Pule, C. Rossig, J. Wu, H. E. Heslop, C. M. Rooney, M. K. Brenner, and G. Dotti, “T lymphocytes redirected against the κ light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells,” Blood 108, 3890-3897 (2006).
[CrossRef] [PubMed]

S. Gottschalk, O. L. Edwards, U. Sili, M. H. Huls, T. Goltsova, A. R. Davis, H. E. Heslop, and C. M. Rooney, “Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies,” Blood 101, 1905-1912 (2003).
[CrossRef]

H. E. Heslop, C. Y. Ng, C. Li, C. A. Smith, S. K. Loftin, R. A. Krance, M. K. Brenner, and C. M. Rooney, “Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes,” Nat. Med. 2, 551-555 (1996).
[CrossRef] [PubMed]

C. M. Rooney, C. A. Smith, C. Y. Ng, S. Loftin, C. Li, R. A. Krance, M. K. Brenner, and H. E. Heslop, “Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation,” Lancet 345, 9-13 (1995).
[CrossRef] [PubMed]

Hess, C.

C. Hess, T. K. Means, P. Autissier, T. Woodberry, M. Altfeld, M. M. Addo, N. Frahm, C. Brander, B. D. Walker, and A. D. Luster, “IL-8 responsiveness defines a subset of CD8 T cells poised to kill,” Blood 104, 3463-3471 (2004).
[CrossRef] [PubMed]

Heymann, J.

N. Meidenbauer, J. Marienhagen, M. Laumer, S. Vogl, J. Heymann, R. Andreesen, and A. Mackensen, “Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients,” J. Immunol. 170, 2161-2169 (2003).
[PubMed]

Hirschi, K.

K. E. Adams, S. Ke, S. Kwon, F. Liang, Z. Fan, Y. Lu, K. Hirschi, M. E. Mawad, M. A. Barry, and E. M. Sevick-Muraca, “Comparison of visible and near-infrared wavelength-excitable fluorescent dyes for molecular imaging of cancer,” J. Biomed. Opt. 12, 024017 (2007).
[CrossRef] [PubMed]

Houston, J. P.

J. P. Houston, S. Ke, W. Wang, C. Li, and E. M. Sevick-Muraca, “Quality analysis of in vivo near-infrared fluorescence and conventional gamma images acquired using a dual-labeled tumor-targeting probe,” J. Biomed. Opt. 10, 054010 (2005).
[CrossRef] [PubMed]

S. Kwon, S. Ke, J. P. Houston, W. Wang, Q. Wu, C. Li, and E. M. Sevick-Muraca, “Imaging dose-dependent pharmacokinetics of an RGD-fluorescent dye conjugate targeted to αvΒ3 receptor expressed in Kaposi's sarcoma,” Mol. Imaging 4, 75-87 (2005).
[PubMed]

Huls, M. H.

S. Gottschalk, O. L. Edwards, U. Sili, M. H. Huls, T. Goltsova, A. R. Davis, H. E. Heslop, and C. M. Rooney, “Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies,” Blood 101, 1905-1912 (2003).
[CrossRef]

Ivanova, A.

G. Koehne, M. Doubrovin, E. Doubrovina, P. Zanzonico, H. F. Gallardo, A. Ivanova, J. Balatoni, J. Teruya-Feldstein, G. Heller, C. May, V. Ponomarev, S. Ruan, R. Finn, R. G. Blasberg, W. Bornmann, I. Riviere, M. Sadelain, R. J. O'Reilly, S. M. Larson, and J. G. Tjuvajev, “Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes,” Nat. Biotechnol. 21, 405-413 (2003).
[CrossRef] [PubMed]

Janier, M. F.

C. Billotey, C. Aspord, O. Beuf, E. Piaggio, F. Gazeau, M. F. Janier, and C. Thivolet, “T-cell homing to the pancreas in autoimmune mouse models of diabetes: in vivo MR imaging,” Radiology (Oak Brook, Ill.) 236, 579-587 (2005).
[CrossRef]

Jensen, M. C.

C. E. Brown, R. P. Vishwanath, B. Aguilar, R. Starr, J. Najbauer, K. S. Aboody, and M. C. Jensen, “Tumor-derived chemokine MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively transferred T cells,” J. Immunol. 179, 3332-3341 (2007).
[PubMed]

Jewell, A. M.

A. M. Leen, U. Sili, B. Savoldo, A. M. Jewell, P. A. Piedra, M. K. Brenner, and C. M. Rooney, “Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications,” Blood 103, 1011-1019 (2003).

Jones, V.

M. S. Mitchell, D. Darrah, D. Yeung, S. Halpern, A. Wallace, J. Voland, V. Jones, and J. Kan-Mitchell, “Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope,” J. Clin. Oncol. 20, 1075-1086(2002).
[CrossRef] [PubMed]

Jordan, E. K.

S. A. Anderson, J. Shukaliak-Quandt, E. K. Jordan, A. S. Arbab, R. Martin, H. McFarland, and J. A. Frank, “Magnetic resonance imaging of labeled T-cells in a mouse model of multiple sclerosis,” Ann. Neurol. 55, 654-659 (2004).
[CrossRef] [PubMed]

Kan-Mitchell, J.

M. S. Mitchell, D. Darrah, D. Yeung, S. Halpern, A. Wallace, J. Voland, V. Jones, and J. Kan-Mitchell, “Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope,” J. Clin. Oncol. 20, 1075-1086(2002).
[CrossRef] [PubMed]

Ke, S.

K. E. Adams, S. Ke, S. Kwon, F. Liang, Z. Fan, Y. Lu, K. Hirschi, M. E. Mawad, M. A. Barry, and E. M. Sevick-Muraca, “Comparison of visible and near-infrared wavelength-excitable fluorescent dyes for molecular imaging of cancer,” J. Biomed. Opt. 12, 024017 (2007).
[CrossRef] [PubMed]

J. P. Houston, S. Ke, W. Wang, C. Li, and E. M. Sevick-Muraca, “Quality analysis of in vivo near-infrared fluorescence and conventional gamma images acquired using a dual-labeled tumor-targeting probe,” J. Biomed. Opt. 10, 054010 (2005).
[CrossRef] [PubMed]

S. Kwon, S. Ke, J. P. Houston, W. Wang, Q. Wu, C. Li, and E. M. Sevick-Muraca, “Imaging dose-dependent pharmacokinetics of an RGD-fluorescent dye conjugate targeted to αvΒ3 receptor expressed in Kaposi's sarcoma,” Mol. Imaging 4, 75-87 (2005).
[PubMed]

W. Wang, S. Ke, Q. Wu, C. Charnsangavej, M. Gurfinkel, J. G. Gelovani, J. L. Abbruzzese, E. M. Sevick-Muraca, and C. Li, “Near-infrared optical imaging of integrin αvΒ3 in human tumor xenografts,” Mol. Imaging 3, 343-351 (2004).
[CrossRef]

S. Ke, X. Wen, M. Gurfinkel, C. Charnsangavej, S. Wallace, E. M. Sevick-Muraca, and C. Li, “Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts,” Cancer Res. 63, 7870-7875 (2003).
[PubMed]

Kenyon, K.

C. Yee, J. A. Thompson, P. Roche, D. R. Byrd, P. P. Lee, M. Piepkorn, K. Kenyon, M. M. Davis, S. R. Riddell, and P. D. Greenberg, “Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo,” J. Exp. Med. 192, 1637-1644 (2000).
[CrossRef] [PubMed]

Koehne, G.

G. Koehne, M. Doubrovin, E. Doubrovina, P. Zanzonico, H. F. Gallardo, A. Ivanova, J. Balatoni, J. Teruya-Feldstein, G. Heller, C. May, V. Ponomarev, S. Ruan, R. Finn, R. G. Blasberg, W. Bornmann, I. Riviere, M. Sadelain, R. J. O'Reilly, S. M. Larson, and J. G. Tjuvajev, “Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes,” Nat. Biotechnol. 21, 405-413 (2003).
[CrossRef] [PubMed]

Krance, R. A.

H. E. Heslop, C. Y. Ng, C. Li, C. A. Smith, S. K. Loftin, R. A. Krance, M. K. Brenner, and C. M. Rooney, “Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes,” Nat. Med. 2, 551-555 (1996).
[CrossRef] [PubMed]

C. M. Rooney, C. A. Smith, C. Y. Ng, S. Loftin, C. Li, R. A. Krance, M. K. Brenner, and H. E. Heslop, “Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation,” Lancet 345, 9-13 (1995).
[CrossRef] [PubMed]

Kwon, S.

K. E. Adams, S. Ke, S. Kwon, F. Liang, Z. Fan, Y. Lu, K. Hirschi, M. E. Mawad, M. A. Barry, and E. M. Sevick-Muraca, “Comparison of visible and near-infrared wavelength-excitable fluorescent dyes for molecular imaging of cancer,” J. Biomed. Opt. 12, 024017 (2007).
[CrossRef] [PubMed]

S. Kwon, S. Ke, J. P. Houston, W. Wang, Q. Wu, C. Li, and E. M. Sevick-Muraca, “Imaging dose-dependent pharmacokinetics of an RGD-fluorescent dye conjugate targeted to αvΒ3 receptor expressed in Kaposi's sarcoma,” Mol. Imaging 4, 75-87 (2005).
[PubMed]

Larson, S. M.

M. M. Doubrovin, E. S. Doubrovina, P. Zanzonico, M. Sadelain, S. M. Larson, and R. J. O'Reilly, “In vivo imaging and quantitation of adoptively transferred human antigen-specific T cells transduced to express a human norepinephrine transporter gene,” Cancer Res. 67, 11959-11969 (2007).
[CrossRef] [PubMed]

G. Koehne, M. Doubrovin, E. Doubrovina, P. Zanzonico, H. F. Gallardo, A. Ivanova, J. Balatoni, J. Teruya-Feldstein, G. Heller, C. May, V. Ponomarev, S. Ruan, R. Finn, R. G. Blasberg, W. Bornmann, I. Riviere, M. Sadelain, R. J. O'Reilly, S. M. Larson, and J. G. Tjuvajev, “Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes,” Nat. Biotechnol. 21, 405-413 (2003).
[CrossRef] [PubMed]

Laumer, M.

N. Meidenbauer, J. Marienhagen, M. Laumer, S. Vogl, J. Heymann, R. Andreesen, and A. Mackensen, “Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients,” J. Immunol. 170, 2161-2169 (2003).
[PubMed]

Lee, P. P.

C. Yee, J. A. Thompson, P. Roche, D. R. Byrd, P. P. Lee, M. Piepkorn, K. Kenyon, M. M. Davis, S. R. Riddell, and P. D. Greenberg, “Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo,” J. Exp. Med. 192, 1637-1644 (2000).
[CrossRef] [PubMed]

Leen, A. M.

A. M. Leen, U. Sili, B. Savoldo, A. M. Jewell, P. A. Piedra, M. K. Brenner, and C. M. Rooney, “Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications,” Blood 103, 1011-1019 (2003).

Leitman, S. F.

B. A. Pockaj, R. M. Sherry, J. P. Wei, J. R. Yannelli, C. S. Carter, S. F. Leitman, J. A. Carasquillo, S. M. Steinberg, S. A. Rosenberg, and J. C. Yang, “Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response,” Cancer Res. 73, 1731-1737(1994).

Li, C.

S. Kwon, S. Ke, J. P. Houston, W. Wang, Q. Wu, C. Li, and E. M. Sevick-Muraca, “Imaging dose-dependent pharmacokinetics of an RGD-fluorescent dye conjugate targeted to αvΒ3 receptor expressed in Kaposi's sarcoma,” Mol. Imaging 4, 75-87 (2005).
[PubMed]

J. P. Houston, S. Ke, W. Wang, C. Li, and E. M. Sevick-Muraca, “Quality analysis of in vivo near-infrared fluorescence and conventional gamma images acquired using a dual-labeled tumor-targeting probe,” J. Biomed. Opt. 10, 054010 (2005).
[CrossRef] [PubMed]

W. Wang, S. Ke, Q. Wu, C. Charnsangavej, M. Gurfinkel, J. G. Gelovani, J. L. Abbruzzese, E. M. Sevick-Muraca, and C. Li, “Near-infrared optical imaging of integrin αvΒ3 in human tumor xenografts,” Mol. Imaging 3, 343-351 (2004).
[CrossRef]

S. Ke, X. Wen, M. Gurfinkel, C. Charnsangavej, S. Wallace, E. M. Sevick-Muraca, and C. Li, “Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts,” Cancer Res. 63, 7870-7875 (2003).
[PubMed]

H. E. Heslop, C. Y. Ng, C. Li, C. A. Smith, S. K. Loftin, R. A. Krance, M. K. Brenner, and C. M. Rooney, “Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes,” Nat. Med. 2, 551-555 (1996).
[CrossRef] [PubMed]

C. M. Rooney, C. A. Smith, C. Y. Ng, S. Loftin, C. Li, R. A. Krance, M. K. Brenner, and H. E. Heslop, “Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation,” Lancet 345, 9-13 (1995).
[CrossRef] [PubMed]

Liang, F.

K. E. Adams, S. Ke, S. Kwon, F. Liang, Z. Fan, Y. Lu, K. Hirschi, M. E. Mawad, M. A. Barry, and E. M. Sevick-Muraca, “Comparison of visible and near-infrared wavelength-excitable fluorescent dyes for molecular imaging of cancer,” J. Biomed. Opt. 12, 024017 (2007).
[CrossRef] [PubMed]

Loftin, S.

C. M. Rooney, C. A. Smith, C. Y. Ng, S. Loftin, C. Li, R. A. Krance, M. K. Brenner, and H. E. Heslop, “Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation,” Lancet 345, 9-13 (1995).
[CrossRef] [PubMed]

Loftin, S. K.

H. E. Heslop, C. Y. Ng, C. Li, C. A. Smith, S. K. Loftin, R. A. Krance, M. K. Brenner, and C. M. Rooney, “Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes,” Nat. Med. 2, 551-555 (1996).
[CrossRef] [PubMed]

Lombardo, C.

C. Botti, D. R. Negri, E. Seregni, V. Ramakrishna, F. Arienti, L. Maffioli, C. Lombardo, A. Bogni, C. Pascali, F. Crippa, S. Massaron, F. Remonti, S. Nerini-Molteni, S. Canevari, and E. Bombardieri, “Comparison of three different methods for radiolabelling human activated T lymphocytes,” Eur. J. Nucl. Med. Mol. Imaging 24, 497-504 (1997).
[CrossRef]

Lu, Y.

K. E. Adams, S. Ke, S. Kwon, F. Liang, Z. Fan, Y. Lu, K. Hirschi, M. E. Mawad, M. A. Barry, and E. M. Sevick-Muraca, “Comparison of visible and near-infrared wavelength-excitable fluorescent dyes for molecular imaging of cancer,” J. Biomed. Opt. 12, 024017 (2007).
[CrossRef] [PubMed]

Luster, A. D.

C. Hess, T. K. Means, P. Autissier, T. Woodberry, M. Altfeld, M. M. Addo, N. Frahm, C. Brander, B. D. Walker, and A. D. Luster, “IL-8 responsiveness defines a subset of CD8 T cells poised to kill,” Blood 104, 3463-3471 (2004).
[CrossRef] [PubMed]

Mackensen, A.

N. Meidenbauer, J. Marienhagen, M. Laumer, S. Vogl, J. Heymann, R. Andreesen, and A. Mackensen, “Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients,” J. Immunol. 170, 2161-2169 (2003).
[PubMed]

Maffioli, L.

C. Botti, D. R. Negri, E. Seregni, V. Ramakrishna, F. Arienti, L. Maffioli, C. Lombardo, A. Bogni, C. Pascali, F. Crippa, S. Massaron, F. Remonti, S. Nerini-Molteni, S. Canevari, and E. Bombardieri, “Comparison of three different methods for radiolabelling human activated T lymphocytes,” Eur. J. Nucl. Med. Mol. Imaging 24, 497-504 (1997).
[CrossRef]

Marienhagen, J.

N. Meidenbauer, J. Marienhagen, M. Laumer, S. Vogl, J. Heymann, R. Andreesen, and A. Mackensen, “Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients,” J. Immunol. 170, 2161-2169 (2003).
[PubMed]

Martin, R.

S. A. Anderson, J. Shukaliak-Quandt, E. K. Jordan, A. S. Arbab, R. Martin, H. McFarland, and J. A. Frank, “Magnetic resonance imaging of labeled T-cells in a mouse model of multiple sclerosis,” Ann. Neurol. 55, 654-659 (2004).
[CrossRef] [PubMed]

Massaron, S.

C. Botti, D. R. Negri, E. Seregni, V. Ramakrishna, F. Arienti, L. Maffioli, C. Lombardo, A. Bogni, C. Pascali, F. Crippa, S. Massaron, F. Remonti, S. Nerini-Molteni, S. Canevari, and E. Bombardieri, “Comparison of three different methods for radiolabelling human activated T lymphocytes,” Eur. J. Nucl. Med. Mol. Imaging 24, 497-504 (1997).
[CrossRef]

Mawad, M. E.

K. E. Adams, S. Ke, S. Kwon, F. Liang, Z. Fan, Y. Lu, K. Hirschi, M. E. Mawad, M. A. Barry, and E. M. Sevick-Muraca, “Comparison of visible and near-infrared wavelength-excitable fluorescent dyes for molecular imaging of cancer,” J. Biomed. Opt. 12, 024017 (2007).
[CrossRef] [PubMed]

May, C.

G. Koehne, M. Doubrovin, E. Doubrovina, P. Zanzonico, H. F. Gallardo, A. Ivanova, J. Balatoni, J. Teruya-Feldstein, G. Heller, C. May, V. Ponomarev, S. Ruan, R. Finn, R. G. Blasberg, W. Bornmann, I. Riviere, M. Sadelain, R. J. O'Reilly, S. M. Larson, and J. G. Tjuvajev, “Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes,” Nat. Biotechnol. 21, 405-413 (2003).
[CrossRef] [PubMed]

McFarland, H.

S. A. Anderson, J. Shukaliak-Quandt, E. K. Jordan, A. S. Arbab, R. Martin, H. McFarland, and J. A. Frank, “Magnetic resonance imaging of labeled T-cells in a mouse model of multiple sclerosis,” Ann. Neurol. 55, 654-659 (2004).
[CrossRef] [PubMed]

Means, T. K.

C. Hess, T. K. Means, P. Autissier, T. Woodberry, M. Altfeld, M. M. Addo, N. Frahm, C. Brander, B. D. Walker, and A. D. Luster, “IL-8 responsiveness defines a subset of CD8 T cells poised to kill,” Blood 104, 3463-3471 (2004).
[CrossRef] [PubMed]

Meidenbauer, N.

N. Meidenbauer, J. Marienhagen, M. Laumer, S. Vogl, J. Heymann, R. Andreesen, and A. Mackensen, “Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients,” J. Immunol. 170, 2161-2169 (2003).
[PubMed]

Mempel, T. R.

F. K. Swirski, C. R. Berger, J. L. Figueiredo, T. R. Mempel, U. H. von Andrian, M. J. Pittet, and R. Weissleder, “A near-infrared cell tracker reagent for multiscopic in vivo imaging and quantification of leukocyte immune responses,” PLoS ONE 2(10), e1075 (24 October 2007).
[CrossRef]

Mitchell, M. S.

M. S. Mitchell, D. Darrah, D. Yeung, S. Halpern, A. Wallace, J. Voland, V. Jones, and J. Kan-Mitchell, “Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope,” J. Clin. Oncol. 20, 1075-1086(2002).
[CrossRef] [PubMed]

Moore, A.

A. Moore, J. Grimm, B. Han, and P. Santamaria, “Tracking the recruitment of diabetogenic CD8+ T-cells to the pancreas in real time,” Diabetes 53, 1459-1466 (2004).
[CrossRef] [PubMed]

Najbauer, J.

C. E. Brown, R. P. Vishwanath, B. Aguilar, R. Starr, J. Najbauer, K. S. Aboody, and M. C. Jensen, “Tumor-derived chemokine MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively transferred T cells,” J. Immunol. 179, 3332-3341 (2007).
[PubMed]

Nakajima, A.

G. L. Costa, M. R. Sandora, A. Nakajima, E. V. Nguyen, C. Taylor-Edwards, A. J. Slavin, C. H. Contag, C. G. Fathman, and J. M. Benson, “Adoptive immunotherapy of experimental autoimmune encephalomyelitis via T cell delivery of the IL-12 p40 subunit,” J. Immunol. 167, 2379-2387 (2001).
[PubMed]

A. Nakajima, C. M. Seroogy, M. R. Sandora, I. H. Tarner, G. L. Costa, C. Taylor-Edwards, M. H. Bachmann, C. H. Contag, and C. G. Fathman, “Antigen-specific T cell-mediated gene therapy in collagen-induced arthritis,” J. Clin. Invest. 107, 1293-1301 (2001).
[CrossRef] [PubMed]

Negri, D. R.

C. Botti, D. R. Negri, E. Seregni, V. Ramakrishna, F. Arienti, L. Maffioli, C. Lombardo, A. Bogni, C. Pascali, F. Crippa, S. Massaron, F. Remonti, S. Nerini-Molteni, S. Canevari, and E. Bombardieri, “Comparison of three different methods for radiolabelling human activated T lymphocytes,” Eur. J. Nucl. Med. Mol. Imaging 24, 497-504 (1997).
[CrossRef]

Negrin, R. S.

J. Hardy, M. Edinger, M. H. Bachmann, R. S. Negrin, C. G. Fathman, and C. H. Contag, “Bioluminescence imaging of lymphocyte trafficking in vivo,” Exp. Hematol. 29, 1353-1360 (2001).
[CrossRef] [PubMed]

Nerini-Molteni, S.

C. Botti, D. R. Negri, E. Seregni, V. Ramakrishna, F. Arienti, L. Maffioli, C. Lombardo, A. Bogni, C. Pascali, F. Crippa, S. Massaron, F. Remonti, S. Nerini-Molteni, S. Canevari, and E. Bombardieri, “Comparison of three different methods for radiolabelling human activated T lymphocytes,” Eur. J. Nucl. Med. Mol. Imaging 24, 497-504 (1997).
[CrossRef]

Ng, C. Y.

H. E. Heslop, C. Y. Ng, C. Li, C. A. Smith, S. K. Loftin, R. A. Krance, M. K. Brenner, and C. M. Rooney, “Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes,” Nat. Med. 2, 551-555 (1996).
[CrossRef] [PubMed]

C. M. Rooney, C. A. Smith, C. Y. Ng, S. Loftin, C. Li, R. A. Krance, M. K. Brenner, and H. E. Heslop, “Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation,” Lancet 345, 9-13 (1995).
[CrossRef] [PubMed]

Nguyen, E. V.

G. L. Costa, M. R. Sandora, A. Nakajima, E. V. Nguyen, C. Taylor-Edwards, A. J. Slavin, C. H. Contag, C. G. Fathman, and J. M. Benson, “Adoptive immunotherapy of experimental autoimmune encephalomyelitis via T cell delivery of the IL-12 p40 subunit,” J. Immunol. 167, 2379-2387 (2001).
[PubMed]

O'Reilly, R. J.

M. M. Doubrovin, E. S. Doubrovina, P. Zanzonico, M. Sadelain, S. M. Larson, and R. J. O'Reilly, “In vivo imaging and quantitation of adoptively transferred human antigen-specific T cells transduced to express a human norepinephrine transporter gene,” Cancer Res. 67, 11959-11969 (2007).
[CrossRef] [PubMed]

G. Koehne, M. Doubrovin, E. Doubrovina, P. Zanzonico, H. F. Gallardo, A. Ivanova, J. Balatoni, J. Teruya-Feldstein, G. Heller, C. May, V. Ponomarev, S. Ruan, R. Finn, R. G. Blasberg, W. Bornmann, I. Riviere, M. Sadelain, R. J. O'Reilly, S. M. Larson, and J. G. Tjuvajev, “Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes,” Nat. Biotechnol. 21, 405-413 (2003).
[CrossRef] [PubMed]

Pascali, C.

C. Botti, D. R. Negri, E. Seregni, V. Ramakrishna, F. Arienti, L. Maffioli, C. Lombardo, A. Bogni, C. Pascali, F. Crippa, S. Massaron, F. Remonti, S. Nerini-Molteni, S. Canevari, and E. Bombardieri, “Comparison of three different methods for radiolabelling human activated T lymphocytes,” Eur. J. Nucl. Med. Mol. Imaging 24, 497-504 (1997).
[CrossRef]

Piaggio, E.

C. Billotey, C. Aspord, O. Beuf, E. Piaggio, F. Gazeau, M. F. Janier, and C. Thivolet, “T-cell homing to the pancreas in autoimmune mouse models of diabetes: in vivo MR imaging,” Radiology (Oak Brook, Ill.) 236, 579-587 (2005).
[CrossRef]

Piedra, P. A.

A. M. Leen, U. Sili, B. Savoldo, A. M. Jewell, P. A. Piedra, M. K. Brenner, and C. M. Rooney, “Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications,” Blood 103, 1011-1019 (2003).

Piepkorn, M.

C. Yee, J. A. Thompson, P. Roche, D. R. Byrd, P. P. Lee, M. Piepkorn, K. Kenyon, M. M. Davis, S. R. Riddell, and P. D. Greenberg, “Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo,” J. Exp. Med. 192, 1637-1644 (2000).
[CrossRef] [PubMed]

Pittet, M. J.

F. K. Swirski, C. R. Berger, J. L. Figueiredo, T. R. Mempel, U. H. von Andrian, M. J. Pittet, and R. Weissleder, “A near-infrared cell tracker reagent for multiscopic in vivo imaging and quantification of leukocyte immune responses,” PLoS ONE 2(10), e1075 (24 October 2007).
[CrossRef]

Pockaj, B. A.

B. A. Pockaj, R. M. Sherry, J. P. Wei, J. R. Yannelli, C. S. Carter, S. F. Leitman, J. A. Carasquillo, S. M. Steinberg, S. A. Rosenberg, and J. C. Yang, “Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response,” Cancer Res. 73, 1731-1737(1994).

Ponomarev, V.

G. Koehne, M. Doubrovin, E. Doubrovina, P. Zanzonico, H. F. Gallardo, A. Ivanova, J. Balatoni, J. Teruya-Feldstein, G. Heller, C. May, V. Ponomarev, S. Ruan, R. Finn, R. G. Blasberg, W. Bornmann, I. Riviere, M. Sadelain, R. J. O'Reilly, S. M. Larson, and J. G. Tjuvajev, “Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes,” Nat. Biotechnol. 21, 405-413 (2003).
[CrossRef] [PubMed]

Pule, M.

J. Vera, B. Savoldo, S. Vigouroux, E. Biagi, M. Pule, C. Rossig, J. Wu, H. E. Heslop, C. M. Rooney, M. K. Brenner, and G. Dotti, “T lymphocytes redirected against the κ light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells,” Blood 108, 3890-3897 (2006).
[CrossRef] [PubMed]

Ramakrishna, V.

C. Botti, D. R. Negri, E. Seregni, V. Ramakrishna, F. Arienti, L. Maffioli, C. Lombardo, A. Bogni, C. Pascali, F. Crippa, S. Massaron, F. Remonti, S. Nerini-Molteni, S. Canevari, and E. Bombardieri, “Comparison of three different methods for radiolabelling human activated T lymphocytes,” Eur. J. Nucl. Med. Mol. Imaging 24, 497-504 (1997).
[CrossRef]

Remonti, F.

C. Botti, D. R. Negri, E. Seregni, V. Ramakrishna, F. Arienti, L. Maffioli, C. Lombardo, A. Bogni, C. Pascali, F. Crippa, S. Massaron, F. Remonti, S. Nerini-Molteni, S. Canevari, and E. Bombardieri, “Comparison of three different methods for radiolabelling human activated T lymphocytes,” Eur. J. Nucl. Med. Mol. Imaging 24, 497-504 (1997).
[CrossRef]

Riddell, S. R.

C. Yee, J. A. Thompson, P. Roche, D. R. Byrd, P. P. Lee, M. Piepkorn, K. Kenyon, M. M. Davis, S. R. Riddell, and P. D. Greenberg, “Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo,” J. Exp. Med. 192, 1637-1644 (2000).
[CrossRef] [PubMed]

Riviere, I.

G. Koehne, M. Doubrovin, E. Doubrovina, P. Zanzonico, H. F. Gallardo, A. Ivanova, J. Balatoni, J. Teruya-Feldstein, G. Heller, C. May, V. Ponomarev, S. Ruan, R. Finn, R. G. Blasberg, W. Bornmann, I. Riviere, M. Sadelain, R. J. O'Reilly, S. M. Larson, and J. G. Tjuvajev, “Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes,” Nat. Biotechnol. 21, 405-413 (2003).
[CrossRef] [PubMed]

Roche, P.

C. Yee, J. A. Thompson, P. Roche, D. R. Byrd, P. P. Lee, M. Piepkorn, K. Kenyon, M. M. Davis, S. R. Riddell, and P. D. Greenberg, “Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo,” J. Exp. Med. 192, 1637-1644 (2000).
[CrossRef] [PubMed]

Rooney, C. M.

J. Vera, B. Savoldo, S. Vigouroux, E. Biagi, M. Pule, C. Rossig, J. Wu, H. E. Heslop, C. M. Rooney, M. K. Brenner, and G. Dotti, “T lymphocytes redirected against the κ light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells,” Blood 108, 3890-3897 (2006).
[CrossRef] [PubMed]

A. M. Leen, U. Sili, B. Savoldo, A. M. Jewell, P. A. Piedra, M. K. Brenner, and C. M. Rooney, “Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications,” Blood 103, 1011-1019 (2003).

S. Gottschalk, O. L. Edwards, U. Sili, M. H. Huls, T. Goltsova, A. R. Davis, H. E. Heslop, and C. M. Rooney, “Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies,” Blood 101, 1905-1912 (2003).
[CrossRef]

H. E. Heslop, C. Y. Ng, C. Li, C. A. Smith, S. K. Loftin, R. A. Krance, M. K. Brenner, and C. M. Rooney, “Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes,” Nat. Med. 2, 551-555 (1996).
[CrossRef] [PubMed]

C. M. Rooney, C. A. Smith, C. Y. Ng, S. Loftin, C. Li, R. A. Krance, M. K. Brenner, and H. E. Heslop, “Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation,” Lancet 345, 9-13 (1995).
[CrossRef] [PubMed]

Rosenberg, S. A.

B. A. Pockaj, R. M. Sherry, J. P. Wei, J. R. Yannelli, C. S. Carter, S. F. Leitman, J. A. Carasquillo, S. M. Steinberg, S. A. Rosenberg, and J. C. Yang, “Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response,” Cancer Res. 73, 1731-1737(1994).

Rossig, C.

J. Vera, B. Savoldo, S. Vigouroux, E. Biagi, M. Pule, C. Rossig, J. Wu, H. E. Heslop, C. M. Rooney, M. K. Brenner, and G. Dotti, “T lymphocytes redirected against the κ light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells,” Blood 108, 3890-3897 (2006).
[CrossRef] [PubMed]

Ruan, S.

G. Koehne, M. Doubrovin, E. Doubrovina, P. Zanzonico, H. F. Gallardo, A. Ivanova, J. Balatoni, J. Teruya-Feldstein, G. Heller, C. May, V. Ponomarev, S. Ruan, R. Finn, R. G. Blasberg, W. Bornmann, I. Riviere, M. Sadelain, R. J. O'Reilly, S. M. Larson, and J. G. Tjuvajev, “Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes,” Nat. Biotechnol. 21, 405-413 (2003).
[CrossRef] [PubMed]

Sadelain, M.

M. M. Doubrovin, E. S. Doubrovina, P. Zanzonico, M. Sadelain, S. M. Larson, and R. J. O'Reilly, “In vivo imaging and quantitation of adoptively transferred human antigen-specific T cells transduced to express a human norepinephrine transporter gene,” Cancer Res. 67, 11959-11969 (2007).
[CrossRef] [PubMed]

G. Koehne, M. Doubrovin, E. Doubrovina, P. Zanzonico, H. F. Gallardo, A. Ivanova, J. Balatoni, J. Teruya-Feldstein, G. Heller, C. May, V. Ponomarev, S. Ruan, R. Finn, R. G. Blasberg, W. Bornmann, I. Riviere, M. Sadelain, R. J. O'Reilly, S. M. Larson, and J. G. Tjuvajev, “Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes,” Nat. Biotechnol. 21, 405-413 (2003).
[CrossRef] [PubMed]

Sandora, M. R.

G. L. Costa, M. R. Sandora, A. Nakajima, E. V. Nguyen, C. Taylor-Edwards, A. J. Slavin, C. H. Contag, C. G. Fathman, and J. M. Benson, “Adoptive immunotherapy of experimental autoimmune encephalomyelitis via T cell delivery of the IL-12 p40 subunit,” J. Immunol. 167, 2379-2387 (2001).
[PubMed]

A. Nakajima, C. M. Seroogy, M. R. Sandora, I. H. Tarner, G. L. Costa, C. Taylor-Edwards, M. H. Bachmann, C. H. Contag, and C. G. Fathman, “Antigen-specific T cell-mediated gene therapy in collagen-induced arthritis,” J. Clin. Invest. 107, 1293-1301 (2001).
[CrossRef] [PubMed]

Santamaria, P.

A. Moore, J. Grimm, B. Han, and P. Santamaria, “Tracking the recruitment of diabetogenic CD8+ T-cells to the pancreas in real time,” Diabetes 53, 1459-1466 (2004).
[CrossRef] [PubMed]

Savoldo, B.

J. Vera, B. Savoldo, S. Vigouroux, E. Biagi, M. Pule, C. Rossig, J. Wu, H. E. Heslop, C. M. Rooney, M. K. Brenner, and G. Dotti, “T lymphocytes redirected against the κ light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells,” Blood 108, 3890-3897 (2006).
[CrossRef] [PubMed]

A. M. Leen, U. Sili, B. Savoldo, A. M. Jewell, P. A. Piedra, M. K. Brenner, and C. M. Rooney, “Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications,” Blood 103, 1011-1019 (2003).

Seregni, E.

C. Botti, D. R. Negri, E. Seregni, V. Ramakrishna, F. Arienti, L. Maffioli, C. Lombardo, A. Bogni, C. Pascali, F. Crippa, S. Massaron, F. Remonti, S. Nerini-Molteni, S. Canevari, and E. Bombardieri, “Comparison of three different methods for radiolabelling human activated T lymphocytes,” Eur. J. Nucl. Med. Mol. Imaging 24, 497-504 (1997).
[CrossRef]

Seroogy, C. M.

A. Nakajima, C. M. Seroogy, M. R. Sandora, I. H. Tarner, G. L. Costa, C. Taylor-Edwards, M. H. Bachmann, C. H. Contag, and C. G. Fathman, “Antigen-specific T cell-mediated gene therapy in collagen-induced arthritis,” J. Clin. Invest. 107, 1293-1301 (2001).
[CrossRef] [PubMed]

Sevick-Muraca, E. M.

K. E. Adams, S. Ke, S. Kwon, F. Liang, Z. Fan, Y. Lu, K. Hirschi, M. E. Mawad, M. A. Barry, and E. M. Sevick-Muraca, “Comparison of visible and near-infrared wavelength-excitable fluorescent dyes for molecular imaging of cancer,” J. Biomed. Opt. 12, 024017 (2007).
[CrossRef] [PubMed]

J. P. Houston, S. Ke, W. Wang, C. Li, and E. M. Sevick-Muraca, “Quality analysis of in vivo near-infrared fluorescence and conventional gamma images acquired using a dual-labeled tumor-targeting probe,” J. Biomed. Opt. 10, 054010 (2005).
[CrossRef] [PubMed]

S. Kwon, S. Ke, J. P. Houston, W. Wang, Q. Wu, C. Li, and E. M. Sevick-Muraca, “Imaging dose-dependent pharmacokinetics of an RGD-fluorescent dye conjugate targeted to αvΒ3 receptor expressed in Kaposi's sarcoma,” Mol. Imaging 4, 75-87 (2005).
[PubMed]

W. Wang, S. Ke, Q. Wu, C. Charnsangavej, M. Gurfinkel, J. G. Gelovani, J. L. Abbruzzese, E. M. Sevick-Muraca, and C. Li, “Near-infrared optical imaging of integrin αvΒ3 in human tumor xenografts,” Mol. Imaging 3, 343-351 (2004).
[CrossRef]

S. Ke, X. Wen, M. Gurfinkel, C. Charnsangavej, S. Wallace, E. M. Sevick-Muraca, and C. Li, “Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts,” Cancer Res. 63, 7870-7875 (2003).
[PubMed]

Sherry, R. M.

B. A. Pockaj, R. M. Sherry, J. P. Wei, J. R. Yannelli, C. S. Carter, S. F. Leitman, J. A. Carasquillo, S. M. Steinberg, S. A. Rosenberg, and J. C. Yang, “Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response,” Cancer Res. 73, 1731-1737(1994).

Shukaliak-Quandt, J.

S. A. Anderson, J. Shukaliak-Quandt, E. K. Jordan, A. S. Arbab, R. Martin, H. McFarland, and J. A. Frank, “Magnetic resonance imaging of labeled T-cells in a mouse model of multiple sclerosis,” Ann. Neurol. 55, 654-659 (2004).
[CrossRef] [PubMed]

Sili, U.

S. Gottschalk, O. L. Edwards, U. Sili, M. H. Huls, T. Goltsova, A. R. Davis, H. E. Heslop, and C. M. Rooney, “Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies,” Blood 101, 1905-1912 (2003).
[CrossRef]

A. M. Leen, U. Sili, B. Savoldo, A. M. Jewell, P. A. Piedra, M. K. Brenner, and C. M. Rooney, “Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications,” Blood 103, 1011-1019 (2003).

Slavin, A. J.

G. L. Costa, M. R. Sandora, A. Nakajima, E. V. Nguyen, C. Taylor-Edwards, A. J. Slavin, C. H. Contag, C. G. Fathman, and J. M. Benson, “Adoptive immunotherapy of experimental autoimmune encephalomyelitis via T cell delivery of the IL-12 p40 subunit,” J. Immunol. 167, 2379-2387 (2001).
[PubMed]

Smith, C. A.

H. E. Heslop, C. Y. Ng, C. Li, C. A. Smith, S. K. Loftin, R. A. Krance, M. K. Brenner, and C. M. Rooney, “Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes,” Nat. Med. 2, 551-555 (1996).
[CrossRef] [PubMed]

C. M. Rooney, C. A. Smith, C. Y. Ng, S. Loftin, C. Li, R. A. Krance, M. K. Brenner, and H. E. Heslop, “Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation,” Lancet 345, 9-13 (1995).
[CrossRef] [PubMed]

Starr, R.

C. E. Brown, R. P. Vishwanath, B. Aguilar, R. Starr, J. Najbauer, K. S. Aboody, and M. C. Jensen, “Tumor-derived chemokine MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively transferred T cells,” J. Immunol. 179, 3332-3341 (2007).
[PubMed]

Steinberg, S. M.

B. A. Pockaj, R. M. Sherry, J. P. Wei, J. R. Yannelli, C. S. Carter, S. F. Leitman, J. A. Carasquillo, S. M. Steinberg, S. A. Rosenberg, and J. C. Yang, “Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response,” Cancer Res. 73, 1731-1737(1994).

Swirski, F. K.

F. K. Swirski, C. R. Berger, J. L. Figueiredo, T. R. Mempel, U. H. von Andrian, M. J. Pittet, and R. Weissleder, “A near-infrared cell tracker reagent for multiscopic in vivo imaging and quantification of leukocyte immune responses,” PLoS ONE 2(10), e1075 (24 October 2007).
[CrossRef]

Tarner, I. H.

A. Nakajima, C. M. Seroogy, M. R. Sandora, I. H. Tarner, G. L. Costa, C. Taylor-Edwards, M. H. Bachmann, C. H. Contag, and C. G. Fathman, “Antigen-specific T cell-mediated gene therapy in collagen-induced arthritis,” J. Clin. Invest. 107, 1293-1301 (2001).
[CrossRef] [PubMed]

Taylor-Edwards, C.

A. Nakajima, C. M. Seroogy, M. R. Sandora, I. H. Tarner, G. L. Costa, C. Taylor-Edwards, M. H. Bachmann, C. H. Contag, and C. G. Fathman, “Antigen-specific T cell-mediated gene therapy in collagen-induced arthritis,” J. Clin. Invest. 107, 1293-1301 (2001).
[CrossRef] [PubMed]

G. L. Costa, M. R. Sandora, A. Nakajima, E. V. Nguyen, C. Taylor-Edwards, A. J. Slavin, C. H. Contag, C. G. Fathman, and J. M. Benson, “Adoptive immunotherapy of experimental autoimmune encephalomyelitis via T cell delivery of the IL-12 p40 subunit,” J. Immunol. 167, 2379-2387 (2001).
[PubMed]

Teruya-Feldstein, J.

G. Koehne, M. Doubrovin, E. Doubrovina, P. Zanzonico, H. F. Gallardo, A. Ivanova, J. Balatoni, J. Teruya-Feldstein, G. Heller, C. May, V. Ponomarev, S. Ruan, R. Finn, R. G. Blasberg, W. Bornmann, I. Riviere, M. Sadelain, R. J. O'Reilly, S. M. Larson, and J. G. Tjuvajev, “Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes,” Nat. Biotechnol. 21, 405-413 (2003).
[CrossRef] [PubMed]

Thivolet, C.

C. Billotey, C. Aspord, O. Beuf, E. Piaggio, F. Gazeau, M. F. Janier, and C. Thivolet, “T-cell homing to the pancreas in autoimmune mouse models of diabetes: in vivo MR imaging,” Radiology (Oak Brook, Ill.) 236, 579-587 (2005).
[CrossRef]

Thompson, J. A.

C. Yee, J. A. Thompson, P. Roche, D. R. Byrd, P. P. Lee, M. Piepkorn, K. Kenyon, M. M. Davis, S. R. Riddell, and P. D. Greenberg, “Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo,” J. Exp. Med. 192, 1637-1644 (2000).
[CrossRef] [PubMed]

Tjuvajev, J. G.

G. Koehne, M. Doubrovin, E. Doubrovina, P. Zanzonico, H. F. Gallardo, A. Ivanova, J. Balatoni, J. Teruya-Feldstein, G. Heller, C. May, V. Ponomarev, S. Ruan, R. Finn, R. G. Blasberg, W. Bornmann, I. Riviere, M. Sadelain, R. J. O'Reilly, S. M. Larson, and J. G. Tjuvajev, “Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes,” Nat. Biotechnol. 21, 405-413 (2003).
[CrossRef] [PubMed]

Vera, J.

J. Vera, B. Savoldo, S. Vigouroux, E. Biagi, M. Pule, C. Rossig, J. Wu, H. E. Heslop, C. M. Rooney, M. K. Brenner, and G. Dotti, “T lymphocytes redirected against the κ light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells,” Blood 108, 3890-3897 (2006).
[CrossRef] [PubMed]

Vigouroux, S.

J. Vera, B. Savoldo, S. Vigouroux, E. Biagi, M. Pule, C. Rossig, J. Wu, H. E. Heslop, C. M. Rooney, M. K. Brenner, and G. Dotti, “T lymphocytes redirected against the κ light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells,” Blood 108, 3890-3897 (2006).
[CrossRef] [PubMed]

Vishwanath, R. P.

C. E. Brown, R. P. Vishwanath, B. Aguilar, R. Starr, J. Najbauer, K. S. Aboody, and M. C. Jensen, “Tumor-derived chemokine MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively transferred T cells,” J. Immunol. 179, 3332-3341 (2007).
[PubMed]

Vogl, S.

N. Meidenbauer, J. Marienhagen, M. Laumer, S. Vogl, J. Heymann, R. Andreesen, and A. Mackensen, “Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients,” J. Immunol. 170, 2161-2169 (2003).
[PubMed]

Voland, J.

M. S. Mitchell, D. Darrah, D. Yeung, S. Halpern, A. Wallace, J. Voland, V. Jones, and J. Kan-Mitchell, “Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope,” J. Clin. Oncol. 20, 1075-1086(2002).
[CrossRef] [PubMed]

von Andrian, U. H.

F. K. Swirski, C. R. Berger, J. L. Figueiredo, T. R. Mempel, U. H. von Andrian, M. J. Pittet, and R. Weissleder, “A near-infrared cell tracker reagent for multiscopic in vivo imaging and quantification of leukocyte immune responses,” PLoS ONE 2(10), e1075 (24 October 2007).
[CrossRef]

Waggoner, A. S.

B. Ballou, L. A. Ernst, and A. S. Waggoner, “Fluorescence imaging of tumors in vivo,” Curr. Med. Chem. 12, 795-805 (2005).
[CrossRef] [PubMed]

Walker, B. D.

C. Hess, T. K. Means, P. Autissier, T. Woodberry, M. Altfeld, M. M. Addo, N. Frahm, C. Brander, B. D. Walker, and A. D. Luster, “IL-8 responsiveness defines a subset of CD8 T cells poised to kill,” Blood 104, 3463-3471 (2004).
[CrossRef] [PubMed]

Wallace, A.

M. S. Mitchell, D. Darrah, D. Yeung, S. Halpern, A. Wallace, J. Voland, V. Jones, and J. Kan-Mitchell, “Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope,” J. Clin. Oncol. 20, 1075-1086(2002).
[CrossRef] [PubMed]

Wallace, S.

S. Ke, X. Wen, M. Gurfinkel, C. Charnsangavej, S. Wallace, E. M. Sevick-Muraca, and C. Li, “Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts,” Cancer Res. 63, 7870-7875 (2003).
[PubMed]

Wang, W.

J. P. Houston, S. Ke, W. Wang, C. Li, and E. M. Sevick-Muraca, “Quality analysis of in vivo near-infrared fluorescence and conventional gamma images acquired using a dual-labeled tumor-targeting probe,” J. Biomed. Opt. 10, 054010 (2005).
[CrossRef] [PubMed]

S. Kwon, S. Ke, J. P. Houston, W. Wang, Q. Wu, C. Li, and E. M. Sevick-Muraca, “Imaging dose-dependent pharmacokinetics of an RGD-fluorescent dye conjugate targeted to αvΒ3 receptor expressed in Kaposi's sarcoma,” Mol. Imaging 4, 75-87 (2005).
[PubMed]

W. Wang, S. Ke, Q. Wu, C. Charnsangavej, M. Gurfinkel, J. G. Gelovani, J. L. Abbruzzese, E. M. Sevick-Muraca, and C. Li, “Near-infrared optical imaging of integrin αvΒ3 in human tumor xenografts,” Mol. Imaging 3, 343-351 (2004).
[CrossRef]

Wei, J. P.

B. A. Pockaj, R. M. Sherry, J. P. Wei, J. R. Yannelli, C. S. Carter, S. F. Leitman, J. A. Carasquillo, S. M. Steinberg, S. A. Rosenberg, and J. C. Yang, “Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response,” Cancer Res. 73, 1731-1737(1994).

Weissleder, R.

F. K. Swirski, C. R. Berger, J. L. Figueiredo, T. R. Mempel, U. H. von Andrian, M. J. Pittet, and R. Weissleder, “A near-infrared cell tracker reagent for multiscopic in vivo imaging and quantification of leukocyte immune responses,” PLoS ONE 2(10), e1075 (24 October 2007).
[CrossRef]

Wen, X.

S. Ke, X. Wen, M. Gurfinkel, C. Charnsangavej, S. Wallace, E. M. Sevick-Muraca, and C. Li, “Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts,” Cancer Res. 63, 7870-7875 (2003).
[PubMed]

Woodberry, T.

C. Hess, T. K. Means, P. Autissier, T. Woodberry, M. Altfeld, M. M. Addo, N. Frahm, C. Brander, B. D. Walker, and A. D. Luster, “IL-8 responsiveness defines a subset of CD8 T cells poised to kill,” Blood 104, 3463-3471 (2004).
[CrossRef] [PubMed]

Wu, J.

J. Vera, B. Savoldo, S. Vigouroux, E. Biagi, M. Pule, C. Rossig, J. Wu, H. E. Heslop, C. M. Rooney, M. K. Brenner, and G. Dotti, “T lymphocytes redirected against the κ light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells,” Blood 108, 3890-3897 (2006).
[CrossRef] [PubMed]

Wu, Q.

S. Kwon, S. Ke, J. P. Houston, W. Wang, Q. Wu, C. Li, and E. M. Sevick-Muraca, “Imaging dose-dependent pharmacokinetics of an RGD-fluorescent dye conjugate targeted to αvΒ3 receptor expressed in Kaposi's sarcoma,” Mol. Imaging 4, 75-87 (2005).
[PubMed]

W. Wang, S. Ke, Q. Wu, C. Charnsangavej, M. Gurfinkel, J. G. Gelovani, J. L. Abbruzzese, E. M. Sevick-Muraca, and C. Li, “Near-infrared optical imaging of integrin αvΒ3 in human tumor xenografts,” Mol. Imaging 3, 343-351 (2004).
[CrossRef]

Yang, J. C.

B. A. Pockaj, R. M. Sherry, J. P. Wei, J. R. Yannelli, C. S. Carter, S. F. Leitman, J. A. Carasquillo, S. M. Steinberg, S. A. Rosenberg, and J. C. Yang, “Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response,” Cancer Res. 73, 1731-1737(1994).

Yannelli, J. R.

B. A. Pockaj, R. M. Sherry, J. P. Wei, J. R. Yannelli, C. S. Carter, S. F. Leitman, J. A. Carasquillo, S. M. Steinberg, S. A. Rosenberg, and J. C. Yang, “Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response,” Cancer Res. 73, 1731-1737(1994).

Yee, C.

C. Yee, J. A. Thompson, P. Roche, D. R. Byrd, P. P. Lee, M. Piepkorn, K. Kenyon, M. M. Davis, S. R. Riddell, and P. D. Greenberg, “Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo,” J. Exp. Med. 192, 1637-1644 (2000).
[CrossRef] [PubMed]

Yeung, D.

M. S. Mitchell, D. Darrah, D. Yeung, S. Halpern, A. Wallace, J. Voland, V. Jones, and J. Kan-Mitchell, “Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope,” J. Clin. Oncol. 20, 1075-1086(2002).
[CrossRef] [PubMed]

Zanzonico, P.

M. M. Doubrovin, E. S. Doubrovina, P. Zanzonico, M. Sadelain, S. M. Larson, and R. J. O'Reilly, “In vivo imaging and quantitation of adoptively transferred human antigen-specific T cells transduced to express a human norepinephrine transporter gene,” Cancer Res. 67, 11959-11969 (2007).
[CrossRef] [PubMed]

G. Koehne, M. Doubrovin, E. Doubrovina, P. Zanzonico, H. F. Gallardo, A. Ivanova, J. Balatoni, J. Teruya-Feldstein, G. Heller, C. May, V. Ponomarev, S. Ruan, R. Finn, R. G. Blasberg, W. Bornmann, I. Riviere, M. Sadelain, R. J. O'Reilly, S. M. Larson, and J. G. Tjuvajev, “Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes,” Nat. Biotechnol. 21, 405-413 (2003).
[CrossRef] [PubMed]

Ann. Neurol.

S. A. Anderson, J. Shukaliak-Quandt, E. K. Jordan, A. S. Arbab, R. Martin, H. McFarland, and J. A. Frank, “Magnetic resonance imaging of labeled T-cells in a mouse model of multiple sclerosis,” Ann. Neurol. 55, 654-659 (2004).
[CrossRef] [PubMed]

Blood

J. Vera, B. Savoldo, S. Vigouroux, E. Biagi, M. Pule, C. Rossig, J. Wu, H. E. Heslop, C. M. Rooney, M. K. Brenner, and G. Dotti, “T lymphocytes redirected against the κ light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells,” Blood 108, 3890-3897 (2006).
[CrossRef] [PubMed]

S. Gottschalk, O. L. Edwards, U. Sili, M. H. Huls, T. Goltsova, A. R. Davis, H. E. Heslop, and C. M. Rooney, “Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies,” Blood 101, 1905-1912 (2003).
[CrossRef]

A. M. Leen, U. Sili, B. Savoldo, A. M. Jewell, P. A. Piedra, M. K. Brenner, and C. M. Rooney, “Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications,” Blood 103, 1011-1019 (2003).

C. Hess, T. K. Means, P. Autissier, T. Woodberry, M. Altfeld, M. M. Addo, N. Frahm, C. Brander, B. D. Walker, and A. D. Luster, “IL-8 responsiveness defines a subset of CD8 T cells poised to kill,” Blood 104, 3463-3471 (2004).
[CrossRef] [PubMed]

Cancer Res.

S. Ke, X. Wen, M. Gurfinkel, C. Charnsangavej, S. Wallace, E. M. Sevick-Muraca, and C. Li, “Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts,” Cancer Res. 63, 7870-7875 (2003).
[PubMed]

M. M. Doubrovin, E. S. Doubrovina, P. Zanzonico, M. Sadelain, S. M. Larson, and R. J. O'Reilly, “In vivo imaging and quantitation of adoptively transferred human antigen-specific T cells transduced to express a human norepinephrine transporter gene,” Cancer Res. 67, 11959-11969 (2007).
[CrossRef] [PubMed]

B. A. Pockaj, R. M. Sherry, J. P. Wei, J. R. Yannelli, C. S. Carter, S. F. Leitman, J. A. Carasquillo, S. M. Steinberg, S. A. Rosenberg, and J. C. Yang, “Localization of 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response,” Cancer Res. 73, 1731-1737(1994).

Curr. Med. Chem.

B. Ballou, L. A. Ernst, and A. S. Waggoner, “Fluorescence imaging of tumors in vivo,” Curr. Med. Chem. 12, 795-805 (2005).
[CrossRef] [PubMed]

Curr. Opin. Chem. Biol.

J. V. Frangioni, “In vivo near-infrared fluorescence imaging,” Curr. Opin. Chem. Biol. 7, 626-634 (2003).
[CrossRef] [PubMed]

Diabetes

A. Moore, J. Grimm, B. Han, and P. Santamaria, “Tracking the recruitment of diabetogenic CD8+ T-cells to the pancreas in real time,” Diabetes 53, 1459-1466 (2004).
[CrossRef] [PubMed]

Eur. J. Nucl. Med. Mol. Imaging

C. Botti, D. R. Negri, E. Seregni, V. Ramakrishna, F. Arienti, L. Maffioli, C. Lombardo, A. Bogni, C. Pascali, F. Crippa, S. Massaron, F. Remonti, S. Nerini-Molteni, S. Canevari, and E. Bombardieri, “Comparison of three different methods for radiolabelling human activated T lymphocytes,” Eur. J. Nucl. Med. Mol. Imaging 24, 497-504 (1997).
[CrossRef]

Exp. Hematol.

J. Hardy, M. Edinger, M. H. Bachmann, R. S. Negrin, C. G. Fathman, and C. H. Contag, “Bioluminescence imaging of lymphocyte trafficking in vivo,” Exp. Hematol. 29, 1353-1360 (2001).
[CrossRef] [PubMed]

J. Biomed. Opt.

K. E. Adams, S. Ke, S. Kwon, F. Liang, Z. Fan, Y. Lu, K. Hirschi, M. E. Mawad, M. A. Barry, and E. M. Sevick-Muraca, “Comparison of visible and near-infrared wavelength-excitable fluorescent dyes for molecular imaging of cancer,” J. Biomed. Opt. 12, 024017 (2007).
[CrossRef] [PubMed]

J. P. Houston, S. Ke, W. Wang, C. Li, and E. M. Sevick-Muraca, “Quality analysis of in vivo near-infrared fluorescence and conventional gamma images acquired using a dual-labeled tumor-targeting probe,” J. Biomed. Opt. 10, 054010 (2005).
[CrossRef] [PubMed]

J. Clin. Invest.

A. Nakajima, C. M. Seroogy, M. R. Sandora, I. H. Tarner, G. L. Costa, C. Taylor-Edwards, M. H. Bachmann, C. H. Contag, and C. G. Fathman, “Antigen-specific T cell-mediated gene therapy in collagen-induced arthritis,” J. Clin. Invest. 107, 1293-1301 (2001).
[CrossRef] [PubMed]

J. Clin. Oncol.

M. S. Mitchell, D. Darrah, D. Yeung, S. Halpern, A. Wallace, J. Voland, V. Jones, and J. Kan-Mitchell, “Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope,” J. Clin. Oncol. 20, 1075-1086(2002).
[CrossRef] [PubMed]

J. Exp. Med.

C. Yee, J. A. Thompson, P. Roche, D. R. Byrd, P. P. Lee, M. Piepkorn, K. Kenyon, M. M. Davis, S. R. Riddell, and P. D. Greenberg, “Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo,” J. Exp. Med. 192, 1637-1644 (2000).
[CrossRef] [PubMed]

J. Immunol.

N. Meidenbauer, J. Marienhagen, M. Laumer, S. Vogl, J. Heymann, R. Andreesen, and A. Mackensen, “Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients,” J. Immunol. 170, 2161-2169 (2003).
[PubMed]

G. L. Costa, M. R. Sandora, A. Nakajima, E. V. Nguyen, C. Taylor-Edwards, A. J. Slavin, C. H. Contag, C. G. Fathman, and J. M. Benson, “Adoptive immunotherapy of experimental autoimmune encephalomyelitis via T cell delivery of the IL-12 p40 subunit,” J. Immunol. 167, 2379-2387 (2001).
[PubMed]

C. E. Brown, R. P. Vishwanath, B. Aguilar, R. Starr, J. Najbauer, K. S. Aboody, and M. C. Jensen, “Tumor-derived chemokine MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively transferred T cells,” J. Immunol. 179, 3332-3341 (2007).
[PubMed]

Lancet

C. M. Rooney, C. A. Smith, C. Y. Ng, S. Loftin, C. Li, R. A. Krance, M. K. Brenner, and H. E. Heslop, “Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation,” Lancet 345, 9-13 (1995).
[CrossRef] [PubMed]

Mol. Imaging

W. Wang, S. Ke, Q. Wu, C. Charnsangavej, M. Gurfinkel, J. G. Gelovani, J. L. Abbruzzese, E. M. Sevick-Muraca, and C. Li, “Near-infrared optical imaging of integrin αvΒ3 in human tumor xenografts,” Mol. Imaging 3, 343-351 (2004).
[CrossRef]

S. Kwon, S. Ke, J. P. Houston, W. Wang, Q. Wu, C. Li, and E. M. Sevick-Muraca, “Imaging dose-dependent pharmacokinetics of an RGD-fluorescent dye conjugate targeted to αvΒ3 receptor expressed in Kaposi's sarcoma,” Mol. Imaging 4, 75-87 (2005).
[PubMed]

Nat. Biotechnol.

G. Koehne, M. Doubrovin, E. Doubrovina, P. Zanzonico, H. F. Gallardo, A. Ivanova, J. Balatoni, J. Teruya-Feldstein, G. Heller, C. May, V. Ponomarev, S. Ruan, R. Finn, R. G. Blasberg, W. Bornmann, I. Riviere, M. Sadelain, R. J. O'Reilly, S. M. Larson, and J. G. Tjuvajev, “Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes,” Nat. Biotechnol. 21, 405-413 (2003).
[CrossRef] [PubMed]

Nat. Med.

H. E. Heslop, C. Y. Ng, C. Li, C. A. Smith, S. K. Loftin, R. A. Krance, M. K. Brenner, and C. M. Rooney, “Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes,” Nat. Med. 2, 551-555 (1996).
[CrossRef] [PubMed]

PLoS ONE

F. K. Swirski, C. R. Berger, J. L. Figueiredo, T. R. Mempel, U. H. von Andrian, M. J. Pittet, and R. Weissleder, “A near-infrared cell tracker reagent for multiscopic in vivo imaging and quantification of leukocyte immune responses,” PLoS ONE 2(10), e1075 (24 October 2007).
[CrossRef]

Radiology (Oak Brook, Ill.)

C. Billotey, C. Aspord, O. Beuf, E. Piaggio, F. Gazeau, M. F. Janier, and C. Thivolet, “T-cell homing to the pancreas in autoimmune mouse models of diabetes: in vivo MR imaging,” Radiology (Oak Brook, Ill.) 236, 579-587 (2005).
[CrossRef]

Supplementary Material (3)

» Media 1: AVI (1069 KB)     
» Media 2: AVI (1708 KB)     
» Media 3: AVI (3064 KB)     

Cited By

OSA participates in CrossRef's Cited-By Linking service. Citing articles from OSA journals and other participating publishers are listed here.

Alert me when this article is cited.


Figures (8)

Fig. 1
Fig. 1

Labeling T cells with NHS ester dye. (a), (b) OKT3-activated T cells were incubated with IRDye700DX at concentrations between 0 and 200 μg / ml and analyzed by flow cytometry for MFI. Costaining with CD3 FITC shows that at 50 μg / ml , > 90 % of T cells are labeled with IRDye700DX. (c) Rested ( > 7   days post OKT3 stimulation) and activated ( > 2   days post stimulation) were labeled with IRDye700DX and analyzed for MFI daily. Activated T cells rapidly lost IRDye700DX signal, whereas nonproliferating T cells retained NIR signal. (Media 1) (d) To demonstrate that IRDye800CW binds to T cells, OKT3-stimulated T cells were incubated with IRDye800CW and then counterstained with Sytox Green. Cells were then fixed to a slide and examined by a confocal microscope fitted with a NIR diode source. Individual stack images were reconstructed to observe the colocalization of IRDye800CW.

Fig. 2
Fig. 2

Confocal microscopy of IRDye800CW-labeled OKT3-activated T cells. This movie is compiled from z-stack images from T cells costained with IRDye800CW and Sytox Green. Reconstruction of the images demonstrates the specific labeling of IRDye800CW on T cells.

Fig. 3
Fig. 3

IRDye800CW does not affect proliferation and function of EBV-specific CTLs. (a) IRDye800CW-labeled and nonlabeled EBV-specific CTLs were stimulated with autologous LCL enumerated for proliferation. No difference in CTL expansion was observed over a 14 day period. (b) IRDye800CW-labeled and nonlabeled CTLs were analyzed for the effect of IRDye800CW binding on cytotoxic function against autologous and allogeneic LCL. Both nonlabeled and IRDye800CW-labeled CTLs were capable of recognizing and lysing autologous LCL but not allogeneic LCL. (c) Labeled and unlabeled control CTLs were compared for IFN-γ production in an ELIspot assay against autologous and allogeneic LCL. IRDye800CW did not affect the ability of CTLs to produce IFN-γ.

Fig. 4
Fig. 4

IRDye800CW allows measurement of biodistribution and migration of CTLs. (Media 2) (Media 3) (a) Athymic nude mice were injected s.c. with LCL cells followed by injection of either IRDye800CW dye alone (left panel) or EBV-specific CTLs labeled with IRDye800CW. After 1 h, mice were imaged for NIR signal. Mice injected with IRDye800CW alone show nonspecific NIR accumulation in the liver, whereas mice injected with CTL + IRDye 800 CW show that CTLs accumulate in the lungs shortly after i.v. injection. (b) After 48 h, mice with injected with IRDye800CW-labeled CTLs were examined for NIR signal. NIR signal accumulation was observed in the tumor site (indicated by an arrow) and nonspecific signal in the kidneys, demonstrating that IRDye800CW labeling can be used to detect migration of CTLs to distant tumor sites.

Fig. 5
Fig. 5

Dynamic imaging of mice injected with IRDye800CW alone or labeled T cells. Mice were injected with IRDye800CW alone in PBS, and images were taken at intervals of 800 ms for 40 min. Mice were injected with T cells labeled with IRDye800CW, and images were taken as above. Compilation of the images to generate a movie shows the accumulation of NIR signal in the lungs and liver of mice injected with IRDye800CW-labeled T cells, whereas mice injected only with dye show only nonspecific signal in the liver.

Fig. 6
Fig. 6

IRDye800CW NIR signal shows specific accumulation to LCL tumors. (a) Analysis of mice with s.c. LCL tumors (indicated by an arrow) demonstrate nonspecific NIR signal in the kidneys (posterior view) and liver (anterior view). However, NIR signal persists within the tumor site for up to 72 h post CTL injection (top left panel). (b) Excision of the LCL tumor and cross sectioning showed NIR signal within the LCL tumor, suggesting CTL infiltration.

Fig. 7
Fig. 7

CTLs infiltrate LCL tumor and are responsible for NIR signal. (a) Excised LCL tumors were sectioned and hematoxylin and eosin stained; (b) by immunohistochemistry for human anti-CD3 antibody. (c) The same tissue slices were subsequently examined on a microscope fitted with NIR filters. These tumor slices show the presence of NIR signal.

Fig. 8
Fig. 8

In vivo migration assays demonstrate specific NIR signal accumulation by CCL5-homing CTLs. (a) EBV-specific CTLs and OKT3 stimulated T cells express the chemokine CCR5 and migrate in response to CCL5 chemokine secretion. Here, EBV-specific CTLs show specific migration towards CCL5 in transwell migration assays. (b) To demonstrate specific NIR signal accumulation by CTLs, nonmodified Karpas tumor cells (K-NT) or Karpas cells transduced with the chemokine CCL5 (K-CCL5) were injected s.c. into the left and right flank, respectively. Next, IRDye800CW-labeled CTLs were injected i.v., and mice were imaged for NIR signal after 48 h. NIR signal accumulated in K-CCL5 tumors but not in K-NT tumors, demonstrating that NIR signal is dependent on migration of CTLs into the tumor tissue rather than any nonspecific accumulation. (c) Both K-NT and K-CCL5 tumors and local inguinal lymph nodes (LN) were excised and imaged for NIR signal. As observed by noninvasive imaging, K-CCL5 showed higher NIR signal than K-NT tumors, indicating that CTL migration was responsible for NIR signal accumulation.

Equations (2)

Equations on this page are rendered with MathJax. Learn more.

α v Β 3
α v Β 3

Metrics